Methods for preparation of glycosphingolipids and uses thereof

ABSTRACT

Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of α-galactosyl ceramide, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are provided, wherein the compounds are immunogenic compounds which serve as ligands for NKT (natural killer T) cells.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.13/344,557 filed Jan. 5, 2012 entitled “METHODS FOR PREPARATION OFGLYCOSPHINGOLIPIDS AND USES THEREOF,” which claims priority to U.S.Provisional Patent Application Ser. No. 61/430,117 filed Jan. 5, 2011entitled “METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USESTHEREOF”, which is incorporated by reference herein.

TECHNICAL FIELD OF THE INVENTION

This present invention relates to novel glycosphingolipid analogues,intermediates for the production thereof. In particular, the inventionrelates to novel processes for the preparation of glycosphingolipids.More particularly, the invention relates to methods for synthesis anduses of novel alpha-linked glycospingolipid compounds.

BACKGROUND OF THE INVENTION

Studies show NKT cells, a unique lymphocyte subpopulation, arecharacterized by the coexpression of an invariant antigen receptor andNK receptors. Human NKT cells (Vα24-Jα18) are activated by a specificglycolipid antigen, in a CD1d-dependent manner. CD1d molecules areheterodimers, composed of a heavy polypeptide chain non-covalentlyassociated with a 2-microglobulin, and have substantial structuralsimilarity to major histocompatibility complex (MHC) class I proteins.After activation, NKT cells exhibit MHC-independent antitumor activityagainst tumor cells in vitro and in vivo through several mechanisms.Activated Vα24 NKT cells produce a high level of cytokines, such asIFN-γ, thereby bridging innate and adaptive immunity through theactivation of other effector cells including dendritic cells (DC), NKcells, and CD8⁺ T cells. NKTs play a regulatory role in the immunesystem, thus they are attractive targets for immunotherapy.

At present, the most well studied CD1d-presented antigen isalpha-galactosylceramide (αGalCer, KRN-7000). It initially drew interestwhen extracts derived from the marine sponge, Agelas mauritianus,demonstrated novel anti-tumor properties. Kirin Beer pharmaceuticalcompany (U.S. Pat. No. 5,849,716). This potent activity was later tracedto a family of alpha-linked glycospingolipids (GSLs), from which αGalCerwas structurally optimized. The GSLs consists of a sugar moietyalpha-linked to a ceramide which is formed by an amide bond of a fattyacid with a long chain base.

Upon activation by αGalCer, NKT cells release proinflammatory (Th1) andimmunomodulatory (Th2) cytokine. The production of T_(H)1 cytokines isthought to correlate with antitumor, antiviral/antibacterial, andadjuvant activities, whereas T_(H)2 cytokine production is thought tosubdue autoimmune diseases. αGalCer has been the subject of clinicaltrials for its anti-cancer potential, but it was terminated during phaseI. The non-specific nature of the cytokine profile induced by αGalCer,both Th1 and Th2, makes it less effective as a therapeutic treatment.This interpretation has encouraged many groups to focus on the searchingfor compounds which increase the selectivity toward either the T_(H)1 orT_(H)2 cytokines response. Wong et al. have synthesized a series ofglycolipids bearing aromatic groups on the acyl side chain and foundthese molecules to skew the cytokine release profile towards a T_(H)1response (J. Am. Chem. Soc. 2006, 128, 9022-9023. US 2007/0238871). Invivo experiment on mice with aggressive lung cancer tumors (TC1 cellline) and breast cancer tumors (4T1 cell line) have showed that the lungcancer-bearing mice treated with the new glycolipids had significantlyprolonged survival time compared to those treated with αGalCer. Inbreast cancer-bearing mice, treatment with the new glycolipids inhibitedthe tumor growth rate by 75% of untreated group, as compared to 50%inhibition in mice treated with α-GalCer (Proc. Natl. Acad. Sci. U.S.A2007, 104, 10299-10304).

Therefore, there is a need for efficient means for synthesis ofalpha-glycosphingolipids, such as αGalCer compounds, as well as a needfor synthesis of novel alpha-glycosphingolipid compounds withimmunomodulatory effects.

SUMMARY OF THE INVENTION

The present invention provides novel methods for synthesizinggalactosylsphingolipids, including novel compounds related toα-galactosyl ceramides and active analogs thereof, such as C34.

The invention provides, in one embodiment, a compound represented by thestructure of formula (1):

wherein R₁=OH, NH₂, NHCOR₂; R₂=H or an alkyl, alkenyl, or alkylterminating in aryl, substituted aryl, heteroaryl, or substitutedheteroaryl; X=alkyl group, alkenyl; R₃, R₄=H, OH; R₅=aryl, substitutedaryl, heteroaryl, or substituted heteroaryl.

In one embodiment of the invention, the compound of formula 1 may beobtained by a process that includes, inter alia, the step of removingthe benzylidene protecting group and hydrogenating of the compoundrepresented by the structure of formula (2):

where PG is a hydroxyl protecting group.

In another embodiment, the hydroxyl protecting group may be benzyl.

In one embodiment of the invention, the compound of formula 2 whereX=(CH₂)₈, R₃=H, R₄=H, R₅=4-F-phenyoxy-phenyl, may be obtained by aprocess which includes, inter alia, the step of amide bond formationbetween compounds of formula (3) and formula (4).

where, in one embodiment, PG is benzyl

where in one embodiment, X=alkyl group, alkenyl, R₃=H, OH, R₄=H, OH,R₅=aryl, substituted aryl, heteroaryl, or substituted heteroaryl.

In one embodiment of the invention, the compound of formula (3), whereinR is benzyl, may be obtained by a process that includes, inter alia, thestep of: reducing the azide group of a compound represented by thestructure of formula (5):

In one embodiment of the invention, the compound of formula 5, whereinPG is benzyl, may be obtained by a process including, inter alia, thestep of: reacting a compound represented by the structure of formula (6)

wherein PG is a hydroxyl protecting group and LG is a leaving group,with a compound represented by the structure of formula (7)

wherein PG is a hydroxyl protecting group, to form an alpha glycosidicbond, thus obtaining the compound of formula (5). In another embodiment,the leaving group of formula (6) may be any one of:

In one embodiment of the invention, the compound of formula 1 may beobtained by a process that includes, inter alia, the step of removingthe benzylidene protecting group and hydrogenating of the compoundrepresented by the structure of formula (8):

wherein PG is hydroxyl protective group. In another embodiment, the PGmay be, inter alia, benzyl.

In one embodiment of the invention, the compound of formula (8) may beobtained by a process including, inter alia, the step of: reacting acompound represented by the structure of formula (9) with a compoundrepresented by alkanoic acid, aryl acid, aryl-alkanoic acid, substitutedaryl-alkanoic acid, and heterocyclic acid.

wherein PG is a hydroxyl protecting group.

In one embodiment of the invention, the compound (9) may be obtainedfrom the process including, inter alia, the step of: reducing the azideof a compound represented by the structure of formula (10)

where PG is hydroxyl protective group.

In one embodiment of the invention, the compound (10) may be obtainedfrom the process including, inter alia, the step of: substituting of acompound represented by the structure if formula (11)

where R is leaving group, thereby obtaining the compound of formula(11).

In another embodiment, the R may be, inter alia, methanesulfonyl ortoluenesulfonyl. In one embodiment of the invention, the compound offormula (11) may be obtained by a process including, inter alia, thestep of: conducting a substitution of the hydroxyl moiety of thecompound represented by the structure of formula (12)

In another embodiment, the substitution may be conducted in the presenceof base and methanesulfonyl chloride or toluenesulfonyl chloride.

In one embodiment of the invention, the compound (12) may be obtainedfrom the process including, inter alia, the step of: hydrolysis of thecompound represented by the structure of formula (13)

where R is hydroxyl protective group, in one embodiment, R is alkylester. In another embodiment, R is acetate.

In one embodiment of the invention, the compound (13) may be obtainedfrom the process including, inter alia, the step of: amide bondformation of the compound represented by the structure of formula (14),

and the compound represented by the structure of formula (4).

In one embodiment of the invention, the compound (14) may be obtainedfrom the process including, inter alia, the step of: reducing the azideof a compound represented by the structure of formula (15).

In one embodiment of the invention, the compound (15) may be obtainedfrom the process including, inter alia, the step of: reacting a compoundrepresented by the structure of formula (16)

wherein PG is a hydroxyl protecting group, LG is a leaving group, and Ris ester, with a compound represented by the structure of formula (7),wherein PG is a hydroxyl protecting group, to form an alpha glycosidicbond, thus obtaining the compound of formula (15).

In another embodiment, the leaving group may be any one of:

In one embodiment of the invention, the compound of formula (17) may beobtained by the process including, inter alia, the step of: removing thehydroxyl protecting group PG1, thereby obtaining the compound of formula(17), the PG1 may be, inter alia, trityl.

These and other aspects will become apparent from the followingdescription of the preferred embodiment taken in conjunction with thefollowing drawings, although variations and modifications therein may beaffected without departing from the spirit and scope of the novelconcepts of the disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and areincluded to further demonstrate certain aspects of the presentdisclosure, the inventions of which can be better understood byreference to one or more of these drawings in combination with thedetailed description of specific embodiments presented herein.

FIG. 1 is a schematic illustration depicting synthesis of C34, A15-21.Scheme 1. Reagents and conditions: (a) TfN₃, K₂CO₃, CuSO₄, DCM, MeOH,H₂O; (b) trityl chloride, triethylamine, toluene; (c) benzyl chloride(BnCl), NaH, DMF, Toluene; (d) HCl, toluene, MeOH; (e) A5, Me₂S₂-Tf₂O,THF, 4 A MS; (f) LiAlH₄, THF; (g) RCO₂H, HBTU, NMM, DCM; (h) Pd(OH)₂,H₂, MeOH, DCM.

FIG. 2 is a schematic illustration depicting synthesis of compoundA23-A25. Scheme 2. Reagents and conditions: (a) Pd(OH)₂, H₂ (80 psi),MeOH, DCM, AcOH; (b) RCO₂H, HBTU, NMM, DCM MeOH.

FIG. 3 is a schematic illustration depicting synthesis of formula (4).Scheme 3.

FIG. 4 is schematic illustration depicting synthesis of compounds C5-C7.Scheme 4. Reagents and conditions: (a) PPh₃, THF, H₂O; (b)Ph(CH₂)_(n)CO₂H, HBTU, NMM, DCM; (c) Pd(OH)₂, H₂, DCM, MeOH.

FIG. 5 is schematic illustration depicting synthesis of compoundsC20-C31. Scheme 5. Reagents and conditions: (a) TsCl, pyridine; (b)NaN₃, DMF; (c) PPh₃, THF, H₂O; (d) RCH₂CO₂H, HBTU, NMM, MeOH, DCM.

FIG. 6 shows glycosphingolipid-induced IL-2 secretion in A20CD1d andmNK1.2 cells system. Data are given as mean±SD; “-” indicates nocompound.

FIG. 7 shows INF-r cytokine secretion results by the splenocytes fromfemale C57BL/6 mouse.

FIG. 8 shows IL-4 cytokine secretion results by the splenocytes fromfemale C57BL/6 mouse.

FIG. 9 shows cytokine secretion ratio which obtained from the comparisonof FIGS. 7 & 8.

DETAILED DESCRIPTION OF THE INVENTION

The terms used in this specification generally have their ordinarymeanings in the art, within the context of the invention, and in thespecific context where each term is used. Certain terms that are used todescribe the invention are discussed below, or elsewhere in thespecification, to provide additional guidance to the practitionerregarding the description of the invention. For convenience, certainterms may be highlighted, for example using italics and/or quotationmarks. The use of highlighting has no influence on the scope and meaningof a term; the scope and meaning of a term is the same, in the samecontext, whether or not it is highlighted. It will be appreciated thatsame thing can be said in more than one way. Consequently, alternativelanguage and synonyms may be used for any one or more of the termsdiscussed herein, nor is any special significance to be placed uponwhether or not a term is elaborated or discussed herein. Synonyms forcertain terms are provided. A recital of one or more synonyms does notexclude the use of other synonyms. The use of examples anywhere in thisspecification including examples of any terms discussed herein isillustrative only, and in no way limits the scope and meaning of theinvention or of any exemplified term. Likewise, the invention is notlimited to various embodiments given in this specification.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention pertains. In the case of conflict, thepresent document, including definitions will control.

The novel methods of the synthesis of formula (1) in general comprisebinding the ceramide with saccharide, but it is also possible to firstbond with the phytosphingosine and then to derive the amino group intothe amide group to complete the formula 1.

As an example of such synthesis, it is also possible to synthesize thecompound represented by formula (1) where galactose C6′ is hydroxylgroup via the following steps (see FIG. 1-3).

Phytosphingosine hydrochloride((2S,3S,4R)-2-amino-1,3,4-octadecanetriol) is a starting material,although there are several methods as described in Curr. Org. Chem.2002, 6, 365-391 for the synthesis of phytosphingosine. The commercialsource—phytosphingosine hydrochloride is prepared from the appropriateyeast fermentation broth which can be obtained a reasonable price inlarge quantities (Evonik Degussa Taiwan Ltd.). The isomeric sphingosineshaving a configuration different from that of the natural sphingosinecan be prepared according to the methods described in Helvetica ChimicaActa 1957, 470, 1145; or Chem. Commun. 1991, 820.

In the first step, the amino group of phytosphingosine was converted toan azido group by a diazo transfer reaction by fresh prepared TfN₃ toafford A1. The preparation of TfN₃ can be found in Tetrahedron Lett1996, 37, 6029-6032. Trityl protection of primary alcohol A1 gave crudeA2 which was directly subjected to benzylation conditions of NaH andBnCl to afford compound A3. In the present route, while benzyl group isemployed as the protective group of the hydroxyl group, otherappropriate groups such as benzoate, (p-methoxy)-benzyl, orisopropylidene may also be used. Toluene was selected as the solvent tosynthesize compounds from A1 to A3. The benzylation reaction of secondalcohols failed to proceed in toluene as sole solvent. To overcome thelow reactivity of the benzylation in toluene, a co-solvent system of 10%DMF in toluene was employed to improve the solubility of NaH andintermediate alkoxide. After aqueous workup, crude A3 was obtained as asolution in toluene and subjected to acidic deprotection to giveglycosyl acceptor A4. Various acid can be used in the trityl groupdeprotection, such as hydrochloride, sulfuric acid, hydrogen bromide,trifluoroacetic acid, BF₃.OEt, nitric acid, acidic resin (e.g. AmberliteIR120®) and so on.

Previously, various glycosylation methods have been applied inglycolipids syntheses, including glycosyl fluoride, glycosyltrichloroacetoimidate, glycosyl bromide and glycosyl iodide²⁰⁻²³.Tetrahedron 1998, 54, 3141-3150; J Org Chem 2005, 70, 10260-10270; J OrgChem 2002, 67, 4559-4564; Chem Commun 2007, 2336-2338. The glycosylimidate has been initially employed in our synthesis with excellentyield (89%) and anomeric selectivity (α/β=9/1). Due to the imidate beingeasily hydrolyzed and usually needed to be prepared fresh, using thisleaving group for glycosylation in the large-scale synthesis mightencounter storage and purification problems. Alternatively,thioglycoside A5 as a donor can be achieved using Lewis acid, such asTMSOTf, Tf₂O, BF₃.OEt₂, TfOH, Me₂S₂-Tf₂O as catalysts and usingmolecular sieves to de-hydrate. Compound A5 contains azido group whichfavors glycosylation, while the amino group of phytosphingosine isprotected by amide or cabamate (t-butyl carbamate) as seen in U.S. Pat.No. 5,849,716; US 2007/0238871; J. Am. Chem. Soc. 2004, 126,13602-13603; J. Org. Chem. 2005, 70, 10260-10270; Tetrahedron 1998, 54,3141-3150; Synthesis 2004, 847-850; Bioorg. Med. Chem. Lett. 2006, 16,2195-2199. The 2-NH and 1-OH may form a intramolecular hydrogen bondingwhich hampers it as a nucleophile to attack the activated glycoside andresults in low yields in glycosylation. After the glycosylation betweenA4 and A5, column purification can afford A6 both in pure α-form, andpure β-form.

Compound A6 which contain azido group can be reduced by using any oflithium aluminium hydride, sodium borohydride, a borane complex,phospine complex, enzyme reduction, hydrogenation, or transferhydrogenation. Instead of using phospine complex which generates sideproduct-phosphine oxide which is difficult to remove, the reduction ofazide by lithium aluminium hydride (LiAlH₄) gave higher purity amine A7.Compound A7 was coupled with various prepared carboxylic acids (see FIG.3 for the preparative methods) to give corresponding amide compounds.Global deprotection of these compounds was achieved under hydrogenolysisconditions in the presence of catalytic Pd(OH)₂ and H₂ in mix solventsof MeOH and CH₂Cl₂ to yield analogues of C34, compounds A15-21.

The reductive dehalogenation of aryl halides on acyl chain is carriedout by the hydrogenation reaction of the chloro- and bromo-acylcontaining compounds. Therefore, to avoid dehalogenation reaction, A6was deprotected and reduced by hydrogenesis in the presence of catalyticPd(OH)₂ and H₂. After that resulting amine A22 was coupled withappropriate acids (see FIG. 3 for the preparation methods) in thecoupling conditions, analogues A23-25 were yielded (FIG. 2). For thisprocess many methods of reaction are known, particularly for amidation.It is also possible to use acyl chloride, and acid anhydride or acarboxylic acid. The carboxylic acid is used in a condensation reactionin the presence of an appropriate condensing agent. The appropriatecondensing agent used in the reaction includes dicyclohexylcarbodiimide(DCC), 1-ethyl-3-(3′dimethylaminopropyl)carbodiimine (EDC), as well as2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluoro-phosphate (HBTU), hydroxybenzotrazole (HOBt) or the like. Inorder to progress rapidly the reaction, an organic base such astriethylamine, pyridine, N-methylmorpholine, dimethylaniline,4-dimethylaminopyridine, N-methylpiperidine, N-methylpyrrolidine isadded. The solvent may be any one inert solvents which will not beinvolved in the reaction such as tetrahydrofuran, ethyl ether, toluene,chloroform, methylene chloride, ethyl acetate, acetone or the like.

For the preparation of various substituted phenylalkanoic acids, theWittig reaction is employed as can be seen in FIG. 3. In this process,the co-bromo-alkanoic acids are mixed with triphenyl phosphine in thepresence of the solvent. The reaction is generally carried out with anappropriate solvent, but when the reaction is low, it can be increasedby performing the reaction in the absence of a solvent. The solvent maybe any of inert solvents which will not be involved in the reaction,e.g. toluene, benzene, diglyme, dimethyl sulfide or the like.

As another example of the synthesis, it is also possible to synthesizethe compound represented by the formula (1) by carrying out varioussubstitutions at galactose C6′ position via the following steps (seeFIG. 4-5).

The synthesis of C6 modified analogues began with compound C1 asdescribed in Org Lett 2002, 4, 1267-1270. Reduction of azide, thenamidation with different commercial aromatic acids and fullydeprotection yielded C5-C6 (FIG. 4, Scheme 4). In addition, to avoid atedious protective group interconvertion for the preparation fromcompound C1, a different strategy was employed in the synthesis of C6″and acyl chain bi-modified compounds (FIG. 5). The C6″ hydroxyl group ofA15 can be tosylated or mesylated by toluene sulfonyl chloride ormethane sulfonyl chloride in the presence of base, such as pyridine,dimethylpyridine, triethylamine, diethylpropylamine, DBU or the like,and then the corresponding tosylate or mesylate group can be substitutedwith azide by sodium azide to give C18. Staudinger reduction of azide,amidation with variety of acids yielded C20-31.

Use of the Compound of the Present Invention

The compounds represented by the formula (1) exhibit the followingphysiological activities, can be used as immunotherapeutic agent againstcancers or as immunostimulating agent against the other diseases.

APC activating activity: IL-2 secretions can be measured in the A20CD1dand mNK1.2 cells system as APC and effector cells as shown in Example 2.

Immunostimulating activity: IFN-γ and Il-4 Cytokine secretions can bemeasured as shown in Example 2 which female C57BL/6 mouse (16w4d) wassacrificed and spleen was harvested for the assay.

Anti-tumor agent: The compound of the present invention has Th1 biasedcytokine secretion profile and can be used an antitumor activity and animmunostimulating effect.

While the compounds in current invention can be used as theimmunotherapeutic agent against tumor they may be used alone or combinedwith chemotherapy or radiotherapy.

The compounds of the present invention as anti-tumor agents orimmunostimulating agent may be administered in any appropriate dosageroutes. The compound is generally formed into a preparation which is inthe form of diluted and formed with a pharmaceutically acceptablecarrier (liposome, or micelle). When the compound of present inventionis used, it can be administrated orally or parent rally to human ormammalian. For example, the compounds of present invention when used asinjection, they can be administered intravenously, intramuscularly,subcutaneously or inhalation in a form such as solution, suspension oremulsion with appropriate solvent. In this case, polysorbatesm ormacrogol, cholesterol can be added as a solubilizing agent, ifnecessary. When the compounds in the present invention are administeredorally, they can be in a form of tablet, powder, granule, or dry syrupinto an appropriate additive.

EXAMPLES

Without intent to limit the scope of the invention, exemplaryinstruments, apparatus, methods and their related results according tothe embodiments of the present invention are given below. Note thattitles or subtitles may be used in the examples for convenience of areader, which in no way should limit the scope of the invention.Moreover, certain theories are proposed and disclosed herein; however,in no way they, whether they are right or wrong, should limit the scopeof the invention so long as the invention is practiced according to theinvention without regard for any particular theory or scheme of action.

Example 1

The synthetic method and physicochemical properties of the compounds ofthe present invention are described below (referring to the number ofcompounds in the process of synthesis, see the reaction schemes as shownin FIG. 1-FIG. 5).

In the schemes shown herein, the following abbreviations are used:

THF: tetrahydrofuran

DMF: N,N-dimethyl formide

MS-4A: Molecule Sieves-4A (dehydrating agent)

CH₂Cl₂: dichloromethane

NMM: N-methyl morpholine

HBTU: O-benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate

TMSOTf: trimethylsilyl trifluoromethansulfonate

Tf₂O: trifluoromethansulfonic anhydride

CDCl₃: dl-chloroform

NMR: nuclear magnetic resonance

HRMS: high resolution mass

ESI: electron spray ionization

The other abbreviations have the same meanings as those in the schemesshown above.

Synthetic Scheme 1 (FIG. 1)

The routes show specifically the process for preparing the compound C34,A13, A14, A15, A16, A18, A19, A20, A21 and the compounds according tothe present invention 1 can also be synthesized in accordance with thisprocess.

Synthesis of (2S,3S,4R)-2-azido-D-ribo-octadecane-1,3,4-triol (A1)

To the solution of sodium azide (64.3 g, 989 mmol) in 250 mL water wasadded dichloromethane (350 mL). The biphasic mixture was cooled to 5° C.in an ice bath and triflic anhydride (47.5 mL, 283 mmol) was added overa 20 min period, keeping the temperature under 10° C. After stirring for2.5 h in an ice bath, the reaction mixture was quenched with 70 mL sat.K₂CO₃. The organic phase was isolated and the aqueous phase wasextracted with CH₂Cl₂ (200 mL). The organic phases were combined toafford triflyl azide solution in dichloromethane. [Caution! Triflylazide is explosive, needed to be stored with solvent.]

To a solution of cupric sulfate (0.35 g, 1.4 mmol) in water (150 mL) wasadded phytosphingosine hydrochloride (highly pure form ofphytosphingosine hydrochloride[(2S,3S,4R)-2-amino-1,3,4-octadecanetriol] from the appropriate yeastfermentation broth is commercial available for a reasonable price inlarge quantities, 50.0 g, 141 mmol), potassium carbonate (29.28 g, 211.9mmol) and methanol (1.0 L). The suspension was cooled to 0-5° C. in asalt ice bath and the triflyl azide solution (in 550 mL CH₂Cl₂) wasadded over a 10 min period. After stirring the reaction mixture for 12 hat rt, the mixture was concentrated. The residue was slurried in water(1.0 L) and stirred at room temperature for 12 h. The precipitate wasfiltered and washed with water (500 mL×2). The residue was dried byazeotropic distillation (70-80° C., 200-250 mmHg) with toluene (1.5 L)to afford (2S,3S,4R)-2-azido-D-ribo-octadecane-1,3,4-triol (A1) (47.0 g,137 mmol, 97%) as off-white solids. mp: 87° C. ¹H-NMR (CD₃OD, 400 MHz) δ3.85 (dd, J=11.6, 3.3 Hz, 1H), 3.69 (dd, J=11.6, 7.9 Hz, 1H), 3.50-3.55(m, 1H), 3.43-3.47 (m, 2H), 1.22-1.60 (m, 26H), 0.83 (t, J=6.4 Hz, 3H).¹³C-NMR (CD₃OD, 100 MHz) δ 74.6, 71.5, 65.3, 61.2, 32.5, 31.7, 29.4,29.4, 29.1, 25.4, 22.4, 13.1. HRMS (ESI) calculated for C₁₈H₃₇N₃O₃Na[M+Na]⁺: 366.2733. found: 366.2729.

Synthesis of(2S,3S,4R)-2-azido-3,4-di-O-benzyl-D-ribo-octadecan-1,3,4-triol (A4)

To the mixture of (2S,3S,4R)-2-azido-D-ribo-octadecane-1,3,4-triol (47.0g, 137 mmol) in toluene (1.0 L) was added triethylamine (46 mL, 332mmol) and trityl chloride (42.0 g, 151 mmol). After stirring at 50-55°C. for 6 h, triethylamine (4.6 mL, 33 mmol) and triphenylmethyl chloride(4.20 g, 15.1 mmol) were added and then stirred for an additional 15 h.Water (1.0 L) was added and the mixture was stirred for 3 min. Theorganic phase was washed with water (1.0 L, 500 mL) and concentrated toafford crude (2S,3S,4R)-2-azido-1-trityl-D-ribo-octadecan-1,3,4-triol(A2). The analytical sample for NMR was purified by columnchromatography. ¹H-NMR (CDCl₃, 400 MHz) δ 7.22-7.47 (m, 15H), 3.62 (dd,J=3.7, 10.1 Hz, 2H), 3.53 (m, 2H), 3.40 (dd, J=6, 10.1 Hz, 1H), 2.35(brs, 1H), 1.83 (brs, 1H), 1.20-1.52 (m, 26H), 0.87 (t, J=6.8 Hz, 3H).¹³C-NMR (CDCl₃, 100 MHz) δ 143.35, 128.54, 128.01, 127.27, 87.78, 74.19,72.18, 63.48, 62.31, 31.90, 31.74, 29.67, 29.64, 29.60, 29.55, 29.34,25.59, 22.67, 14.10.

To the solution of crude(2S,3S,4R)-2-azido-1-trityl-D-ribo-octadecan-1,3,4-triol (A2) in toluene(750 mL) and DMF (75 mL) was added sodium hydride (60% in mineral oil,21.9 g, 548 mmol) in three portions over a 10 min period. The mixturewas stirred for 30 min after which benzyl chloride (50.5 mL, 0.438 mmol)was added to the reaction mixture. The mixture was warmed to 50-60° C.and stirred for 18 h. The mixture was then cooled to 0° C. and water (50mL) was added dropwise. The organic phase was washed with sat. ammoniumchloride (500 mL×2) and water (500 mL×2). The organic phase was filteredthrough Celite pad and the filtrate was concentrated to afford crude(2S,3S,4R)-2-azido-2,3-di-benzyl-1-trityl-D-ribo-octadecan-1,3,4-triol(A3).

To the solution of A3 in toluene/methanol (600 mL, 1/1) was addedaqueous HCl (33%, 6.0 mL). The mixture was warmed to 50-60° C. andstirred for 20 h. The reaction mixture was quenched with 1.0 N NaOH (55mL) and concentrated. The residue was partitioneded with toluene (500mL) and water (500 mL). The organic phase was concentrated and theresidue was purified by column chromatography (crude 100 g, silica gel500 g, ethyl acetate/n-hexane=1/10) to afford(2S,3S,4R)-2-azido-2,3-di-benzyl-D-ribo-octadecan-1,3,4-triol (A4) (27.5g, 52.5 mmol, 38% over 4 steps) as yellow oil. ¹H-NMR (CDCl₃, 200 MHz) δ7.26-7.39 (m, 10H), 4.69 (d, J=1.4 Hz, 2H), 4.59 (d, J=4.3 Hz, 2H),3.59-3.94 (m, 5H), 1.26-1.61 (m, 26H), 0.88 (t, J=6.4 Hz, 3H). ¹³C-NMR(CDCl₃, 50 MHz) δ 137.9, 137.6, 128.5, 128.4, 128.1, 127.97, 127.81,127.10, 80.38, 78.96, 73.59, 72.49, 63.03, 62.20, 21.90, 30.16, 29.66,29.35, 25.43, 22.67, 14.11. HRMS (ESI) calculated for C₃₂H₄₉N₃O₃Na[M+Na]⁺: 546.3672. found: 546.3689.

Synthesis of 4-methylphenyl2,3-O-dibenzyl-4,6-O-benzylidene-1-thiol-D-galacto pyranoside (A5)

Compound A5 may be prepared according to the method described inPlettenburg, O. et al. J. Org. chem. 2002, 67, 4559-4564.

Data of compound A5: ¹H-NMR (CDCl₃, 400 MHz) δ 7.58 (d, J=8.1 Hz, 1H),7.50 (m, 2H), 7.23-7.42 (m, 15H), 6.98 (d, J=8.0 Hz, 1H), 5.46 (s, 1H),4.69 (m, 4H), 3.54 (d, J=9.5 Hz, 1H), 4.35 (dd, J=12.3, 1.5 Hz, 1H),4.12 (d, J=3.2 Hz, 1H), 4.03 (dd, J=9.8, 3.6 Hz, 1H), 3.82 (t, J=9.3 Hz,1H), 3.60 (dd, J=9.2, 3.4 Hz, 1H), 3.39 (s, 1H), 2.28 (s, 3H).

Synthesis of2-azido-3,4-di-O-benzyl-1-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-D-ribo-octadecan-1,3,4-triol(A6)

To the solution of dimethyl disulfide (10.0 mL, 113 mmol) indichloromethane (75 mL) was added triflic anhydride (17 mL, 100 mmol) at0-5° C. in a salt ice bath. After stirring the reaction mixture in thesalt ice bath for 30 min, Me₂S₂-Tf₂O was obtained as a 1.0 M solution indichloromethane and it can be stored in an ice bath for 3 hours.

Compound A4 (27.3 g, 52.2 mmol), A5 (34.7 g, 62.6 mmol) and 4 Amolecular sieve (33 g) were mixed and dried under vacuum for 1 h and THF(520 mL) was added to the mixture. The mixture was cooled to −10° C. ina salt ice bath before adding Me₂S₂-Tf₂O (1.0 M solution in CH₂Cl₂, 94mL, 94 mmol). After stirring for 20 min, the reaction mixture wasquenched with triethylamine (22 mL) and then diluted withdichloromethane (200 mL). The mixture was filtered through Celite andwashed with dichloromethane (50 mL). The combined filtrate wasconcentrated and partitioned with dichloromethane (500 mL) and water(500 mL). The organic phase was concentrated and the residue waspurified by column chromatography (crude weight=153 g, 600 g silica gel,ethyl acetate: n-hexane=1:15 to 1:12 to 1:10) to afford2-azido-3,4-di-O-benzyl-1-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-D-ribo-octadecan-1,3,4-triol(A6) (32.07 g, 33.60 mmol, 64%) as off-white wax. mp: 59° C. ¹H-NMR(CDCl₃, 400 MHz) δ 7.22-7.50 (m, 25H), 5.44 (s, 1H), 4.96 (d, J=3.4 Hz,1H), 4.85 (d, J=11.9 Hz, 1H), 4.79 (d, J=12.3 Hz, 1H), 4.73 (d, J=12.3Hz, 1H), 4.66-4.69 (m, 2H), 4.59 (d, J=8.5 Hz, 1H), 4.56 (d, J=12.8 Hz,1H), 4.48 (d, J=11.5 Hz, 1H), 4.15 (d, J=2.8 Hz, 1H), 4.06-4.12 (m, 1H),3.98-4.04 (m, 3H), 3.86 (dd, J=12.5, 1.5 Hz, 1H), 3.68-3.73 (m, 3H),3.60-3.62 (m, 1H), 3.55 (s, 1H), 1.25-1.55 (m, 26H), 0.87 (t, J=7.1 Hz,3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 138.75, 138.36, 138.01, 137.82, 128.85,128.37, 128.34, 128.26, 128.22, 128.09, 127.90, 127.79, 127.75, 127.70,127.66, 127.61, 127.50, 127.45, 126.33, 101.05, 99.13, 79.41, 78.95,76.68, 75.80, 75.44, 74.66, 73.77, 73.49, 72.06, 72.03, 69.31, 68.43,62.97, 61.80, 31.91, 30.01, 29.75, 29.69, 29.67, 29.65, 29.63, 29.60,29.35, 25.44, 22.68, 14.10. [α]_(D) ²⁵ +63.1 (c 1.0, CHCl₃). HRMS (ESI)calculated for C₅₉H₇₅N₃O₈Na [M+Na]⁺: 976.5452. found: 976.5483.

Synthesis of3,4-di-O-benzyl-1-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-2-(11-(4-(4-fluorophenoxy)phenyl)undecanoyl)amino-D-ribo-octadecan-1,3,4-triol(A8)

To the solution of compound A7 (32.07 g, 33.61 mmol) in THF (340 mL) wascooled in an ice bath and lithium aluminum hydride (1.910 g, 50.33 mmol)was added in two portions. The mixture was returned to room temperature(rt) and stirred for 70 min. The mixture was cooled to 0° C. beforesubsequently quenching with water (1.9 mL), 1.0 N NaOH (3.8 mL) andwater (1.9 mL). The mixture was filtered through Celite pad and washedwith dichloromethane (100 mL). The filtrate was concentrated andpartitioned with dichloromethane (350 mL) and water (350 mL).

11-(4-(4-Fluorophenoxy)phenyl))undecanoic acid (B4) (11.27 g, 30.26mmol) was added to the isolated organic phase, followed by NMM (9.2 mL,84 mmol) and HBTU (19.12 g, 50.41 mmol). After stirring at roomtemperature for 12 h, the mixture was filtered and washed with 50 mLCH₂Cl₂. The combined filtrate was washed with sat. ammonium chloride(400 mL) and water (400 mL). The organic phase was concentrated andpurified by column chromatography (crude weight=46 g, 350 g silica gel,ethyl acetate/n-hexane=1/6 to 1/5 to 1/4) to afford A8 (36.06 g, 28.11mmol, 84%) as off-white wax. ¹H-NMR (CDCl₃, 400 MHz) δ 6.86-7.51 (m,33H), 5.84 (d, J=8.0 Hz, 1H), 5.44 (s, 1H), 4.94 (d, J=3.5 Hz, 1H), 4.83(d, J=11.6 Hz, 1H), 4.69-4.74 (m, 3H), 4.63 (d, J=11.6 Hz, 1H), 4.57 (d,J=11.6 Hz, 1H), 4.50 (d, J=3.9 Hz, 1H), 4.47 (d, J=3.9 Hz, 1H),4.24-4.31 (m, 1H), 4.16 (d, J=3.1 Hz, 1H) 4.03-4.12 (m, 3H), 3.92 (dd,J=10.3, 3.6 Hz, 2H), 3.73-3.79 (m, 2H), 3.56 (s, 1H), 3.51-3.53 (m, 1H),2.55 (t, J=7.6 Hz, 2H), 1.87-1.91 (m, 2H), 1.19-1.69 (m, 42H), 0.87 (t,J=6.6 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 172.89, 159.76, 157.36,155.36, 153.36, 153.33, 138.63, 138.52, 138.50, 138.38, 137.81, 137.79,129.53, 128.84, 128.64, 128.42, 128.35, 128.31, 128.29, 128.08, 127.88,127.80, 127.69, 127.59, 127.57, 127.55, 126.29, 120.08, 120.00, 118.31,116.24, 116.01, 100.99, 99.59, 79.81, 79.48, 76.68, 76.14, 75.68, 74.33,73.81, 73.28, 71.88, 71.69, 69.39, 68.13, 62.91, 60.36, 50.32, 36.69,35.17, 31.90, 31.61, 30.24, 29.78, 29.69, 29.67, 29.65, 29.59, 29.56,29.51, 29.42, 29.35, 29.29, 25.81, 25.68, 22.66, 14.17, 14.10. HRMS(ESI) calculated for C₈₂H₁₀₅FNO₁₀ [M+H]⁺: 1282.7723. found: 1282.7731.

Synthesis of 1-O-(α-D-galactopyranosyl)-2-(11-(4-(4-fluorophenoxy)phenyl) undecanoyl) amino-D-ribo-octadecan-1,3,4-triol (C34)

To the solution of A8 (36.06 g, 28.11 mmol) in dichloromethane/methanol(200 mL, dichloromethane/methanol=1/1) was added palladium hydroxide(1.8 g). The mixture was stirred under hydrogen (5 bar) at roomtemperature for 10 h. The reaction mixture was filtered through Celitepad and washed with dichloromethane/methanol (100 mL,dichloromethane/methanol=1/1). The combined filtrate was concentratedand purified by column chromatography (300 g silica gel,dichloromethane/methanol=15/1 to 10/1) to afford crude C34 (17.46 g,20.93 mmol, purity=95.72 area % by HPLC) as off-white solids in 75%yield. Ethanol (87.5 mL) was added to the crude C34 and warmed to 50°C., acetone (87.5 mL) was then added. The solution was cooled to rt overa 3 h period and then cooled in an ice bath. The precipitate wasfiltered and washed with acetone (200 mL) to afford C34 (16.02 g, 19.21mmol 68%, purity=97.15 area % by HPLC) as white solids in 92% recovery.mp: 163° C. ¹H-NMR (CDCl₃/CD₃OD=1/1, 400 MHz) δ 7.26 (d, J=8.5 Hz, 2H),7.07-7.17 (m, 4H), 7.00 (dd, J=6.6, 2.0 Hz, 2H), 5.03 (d, J=3.7 Hz, 1H),4.33 (q, J=4.7 Hz, 1H), 4.05 (d, J=2.7 Hz, 1H), 4.01 (dd, J=4.6, 10.8Hz, 1H), 3.79-3.97 (m, 6H), 3.64-3.72 (m, 2H), 2.71 (t, J=7.4 Hz, 2H),2.34 (t, J=7.5 Hz, 2H), 1.29-1.43 (m, 42H), 1.01 (t, J=6.6 Hz, 3H).¹³C-NMR (CDCl₃/CD₃OD=1/1, 100 MHz) δ 173.99, 154.82, 152.97, 137.34,128.95, 119.39, 119.31, 117.71, 115.52, 115.29, 99.21, 73.92, 71.28,70.41, 69.69, 69.17, 68.37, 66.63, 61.12, 49.92, 35.74, 34.50, 31.66,31.27, 31.02, 29.10, 29.06, 28.99, 28.95, 28.88, 28.85, 28.77, 28.70,28.60, 25.28, 25.23, 21.99, 13.10. [α]_(D) ²⁵ +57.0 (c 1.0,CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI) calculated for C₄₇H₇₇FNO₃ [M+H]⁺:834.5532. found: 834.5595.

Synthesis of3,4-di-O-benzyl-1-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-2-(11-(4-phenoxyphenyl)undecanoyl)amino-D-ribo-octadecan-1,3,4-triol (A9)

By the similar procedure of synthesis of A8, compound A6 (100 mg, 0.105mmol) and compound B12 (33 mg, 0.093 mmol) are the starting materials togive compound A9 (45 mg, 0.036 mmol, 38%) as white wax. ¹H-NMR (CDCl₃,400 MHz) δ 7.48-7.52 (m, 2H), 7.20-7.41 (m, 25H), 7.12 (d, J=8.8 Hz,2H), 7.06 (t, J=7.3 Hz, 1H), 6.96-7.00 (m, 2H), 6.92 (d, J=10.4 Hz, 2H),5.83 (d, J=8.4 Hz, 1H), 5.45 (s, 1H), 4.94 (d, J=3.6, 1H), 4.84 (d,J=11.6 Hz, 1H), 4.69-4.75 (m, 3H), 4.63 (d, J=11.6 Hz, 1H), 4.57 (d,J=11.6 Hz, 1H), 4.49 (d, J=11.6 Hz, 1H), 4.48 (d, J=11.6 Hz, 1H),4.24-4.31 (m, 1H), 4.17 (d, J=3.2 Hz, 1H) 4.03-4.12 (m, 3H), 3.87-3.96(m, 3H), 3.74-3.80 (m, 2H), 3.56 (s, 1H), 3.50-3.56 (m, 1H), 2.57 (t,J=7.6 Hz, 2H), 1.82-1.95 (m, 2H), 1.15-1.65 (m, 42H), 0.88 (t, J=6.6 Hz,3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 172.89, 159.69, 154.86, 138.62, 138.51,138.50, 138.38, 137.89, 137.79, 129.60, 129.49, 128.83, 128.41, 128.34,128.31, 128.29, 128.07, 127.87, 127.82, 127.80, 127.68, 127.57, 127.55,126.29, 122.79, 118.92, 118.41, 100.98, 99.60, 79.82, 79.48, 76.14,75.68, 74.33, 73.80, 73.27, 71.88, 71.69, 69.38, 68.14, 62.91, 50.32,36.70, 35.21, 31.90, 31.61, 30.24, 29.78, 29.69, 29.67, 29.65, 29.59,29.56, 29.51, 29.41, 29.34, 29.29, 25.80, 25.68, 22.66, 14.10. HRMS(ESI) calculated for C₈₂H₁₀₆NO₁₀ [M+H]⁺: 1264.7817. found: 1264.7834.

Synthesis of3,4-di-O-benzyl-1-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-2-(11-(4-isopropoxyphenyl)undecanoyl)amino-D-ribo-octadecan-1,3,4-triol(A10)

By the similar procedure of synthesis of A8, compound A6 (100 mg, 0.105mmol) and B13 (30 mg, 0.094 mmole) were used as starting materials toafford A10 (72.0 mg, 0.059 mmol, 63%) as white wax. ¹H-NMR (CDCl₃, 400MHz) δ 7.21-7.55 (m, 25H), 7.06 (d, J=8.4 Hz, 2H), 7.78-7.84 (m, 2H),5.86 (d, J=8.4 Hz, 1H), 5.46 (s, 1H), 4.95 (d, J=3.2, 1H), 4.85 (d,J=11.6 Hz, 1H), 4.71-4.80 (m, 3H), 4.63 (d, J=11.6 Hz, 1H), 4.58 (d,J=11.6 Hz, 1H), 4.46-4.54 (m, 3H), 4.18 (d, J=3.2 Hz, 1H), 4.05-4.14 (m,3H), 3.88-3.97 (m, 3H), 3.75-3.82 (m, 2H), 3.58 (s, 1H), 3.51-3.57 (m,1H), 2.53 (t, J=7.6 Hz, 2H), 1.83-1.96 (m, 2H), 1.15-1.71 (m, 48H), 0.89(t, J=6.6 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 172.84, 139.68, 138.60,138.49, 138.46, 138.36, 137.77, 128.81, 128.39, 128.32, 128.28, 128.26,128.05, 127.86, 127.79, 127.78, 127.66, 127.54, 126.26, 124.00, 116.89,116.72, 100.96, 99.54, 79.75, 79.46, 76.10, 75.66, 74.29, 73.79, 73.25,71.84, 71.65, 69.35, 68.08, 62.88, 50.28, 36.66, 35.04, 31.87, 31.20,30.19, 29.75, 29.67, 29.64, 29.50, 29.48, 29.38, 29.37, 29.31, 29.04,25.87, 25.64, 22.64, 14.07. HRMS (ESI) calculated for C₇₉H₁₀₈NO₁₀[M+H]⁺: 1230.7973. found: 1230.7968.

Synthesis of3,4-di-O-benzyl-1-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-2-(11-(3,4-difluorophenyl)undecanoyl)amino-D-ribo-octadecan-1,3,4-trio1 (A11)

By the similar procedure of synthesis of A8, compound A7 (100 mg, 0.105mmol) and B14 (28 mg, 0.093 mmole) were used as starting materials toafford A11 (63 mg, 0.052 mmol, 56%). mp: 98° C. ¹H-NMR (CDCl₃, 400 MHz)δ 7.21-7.54 (m, 25H), 6.92-7.06 (m, 2H), 6.81-6.87 (m, 1H), 5.87 (d,J=8.4 Hz, 1H), 5.45 (s, 1H), 4.95 (d, J=3.2, 1H), 4.84 (d, J=11.6 Hz,1H), 4.69-4.79 (m, 3H), 4.63 (d, J=11.6 Hz, 1H), 4.58 (d, J=11.6 Hz,1H), 4.50 (d, J=11.6 Hz, 1H), 4.49 (d, J=11.6 Hz, 1H), 4.25-4.33 (m,1H), 4.17 (d, J=2.8 Hz, 1H) 4.04-4.13 (m, 2H), 3.88-3.97 (m, 3H),3.74-3.81 (m, 2H), 3.57 (s, 1H), 3.51-3.56 (m, 1H), 2.54 (t, J=7.6 Hz,2H), 1.82-1.96 (m, 2H), 1.15-1.69 (m, 42H), 0.89 (t, J=6.8 Hz, 3H).¹³C-NMR (CDCl₃, 100 MHz) δ 172.84, 150.02 (dd, J=245, 13 Hz), 148.55(dd, J=244, 13 Hz), 139.68, 138.60, 138.49, 138.46, 138.36, 137.77,128.81, 128.39, 128.32, 128.28, 128.26, 128.05, 127.86, 127.79, 127.78,127.66, 127.54, 126.26, 124.00, 116.89, 116.72, 100.96, 99.54, 79.75,79.46, 76.01, 75.66, 74.29, 73.79, 73.25, 71.84, 71.65, 69.35, 68.08,62.88, 50.28, 36.66, 35.04, 31.87, 31.20, 30.19, 29.75, 29.67, 29.64,29.50, 29.48, 29.38, 29.37, 29.31, 29.04, 25.78, 25.64, 22.64, 14.07.HRMS (ESI) calculated for C₇₆H₁₀₀F₂NO₉ [M+H]⁺: 1208.7366. found:1208.7398.

Synthesis of3,4-di-O-benzyl-1-O-(2,3-di-O-benzy-4,6-O-benzylidene-α-D-galactopyranosyl)-2-(11-(2,4-difluorophenyl)undecanoyl)amino-D-ribo-octadecan-1,3,4-triol(A12)

By the similar procedure of synthesis of A8, compound A6 (100 mg, 0.105mmol) and B15 (28 mg, 0.093 mmole) were used as starting materials toafford A12 (70 mg, 0.058 mmol, 62%) as white wax. ¹H-NMR (CDCl₃, 400MHz) δ 7.20-7.55 (m, 25H), 7.04-7.14 (m, 1H), 6.69-6.81 (m, 2H), 5.89(d, J=8.3 Hz, 1H), 5.45 (s, 1H), 4.95 (d, J=3.2 Hz, 1H), 4.85 (d, J=11.6Hz, 1H), 4.70-4.79 (m, 3H), 4.64 (d, J=11.6 Hz, 1H), 4.58 (d, J=11.6 Hz,1H), 4.50 (d, J=11.6 Hz, 1H), 4.49 (d, J=11.6 Hz, 1H), 4.25-4.33 (m,1H), 4.17 (d, J=2.8 Hz, 1H) 4.04-4.13 (m, 2H), 3.88-3.97 (m, 3H),3.74-3.80 (m, 2H), 3.57 (s, 1H), 3.51-3.56 (m, 1H), 2.57 (t, J=7.6 Hz,2H), 1.82-1.96 (m, 2H), 1.15-1.69 (m, 42H), 0.88 (t, J=6.6 Hz, 3H).¹³C-NMR (CDCl₃, 100 MHz) δ 172.90, 162.30, 138.59, 138.50, 138.45,138.36, 137.78, 130.89, 128.82, 128.40, 128.33, 128.30, 128.27, 128.06,127.87, 127.79, 127.68, 127.55, 126.27, 110.07, 103.41, 99.53, 79.75,79.47, 76.11, 75.67, 74.29, 73.81, 73.27, 71, 85, 71.65, 69.36, 68.05,62.89, 50.29, 36.67, 31.88, 30.19, 30.15, 29.76, 29.67, 29.65, 29.51,29.37, 29.32, 29.17, 28.38, 25.78, 25.66, 22.65, 14.08. HRMS (ESI)calculated for C₇₆H₁₀₀F₂NO₉ [M+H]⁺: 1208.7366. found: 1208.7377.

Synthesis of 1-O-(α-D-galactopyranosyl)-2-(11-(4-phenoxyphenyl)undecanoyl) amino-D-ribo-1,3,4-octadecantriol (A15)

By the procedure similar to C34, A15 (21 mg, 0.026 mmol, 72%) wasobtained form A9 (45 mg, 0.036 mmol), as off-white solids. mp: 131° C.¹H-NMR (CD₃OD/CDCl₃=1/1, 400 MHz) δ 7.45 (t, J=8.3 Hz, 2H), 7.28 (d,J=7.7 Hz, 2H), 7.20 (t, J=7.3 Hz, 1H), 7.10 (d, J=8.1 Hz, 2H), 7.04 (d,J=8.1 Hz, 2H), 5.04 (d, J=3.3 Hz, 1H), 4.26 (q, J=7.1 Hz, 1H), 3.79-4.13(m, 10H), 2.73 (t, J=7.7 Hz, 2H), 2.36 (t, J=7.5 Hz, 2H), 1.65-1.82 (m,4H), 1.41 (brs, 38H), 0.89 (t, J=7.5 Hz, 3H). ¹³C-NMR (CD₃OD/CDCl₃=1/1,100 MHz) δ 174.09, 157.18, 154.36, 137.40, 128.98, 128.92, 122.22,118.25, 117.71, 99.18, 73.88, 71.30, 70.41, 69.68, 69.17, 68.37, 66.63,61.10, 60.01, 35.80, 34.56, 31.61, 31.29, 31.04, 29.08, 29.02, 28.91,28.80, 28.72, 28.64, 25.30, 22.01, 19.90, 13.15. [α]_(D) ²⁵ +37.4 (c1.0, CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI) calculated for C₄₇H₇₈NO₁₀ [M+H]⁺:816.5626. found: 816.5637.

Synthesis of 1-O-(α-D-Galactopyranosyl)-2-(11-(4-isopropoxy)phenyl)undecanoyl) amino-D-ribo-1,3,4-octadecantriol (A16)

By the procedure similar to C34, compound A16 (34 mg, 0.044 mmol, 74%)was obtained from A10 (72 mg, 0.059 mmol). The data of A16: mp: 120° C.¹H-NMR (CD₃OD/CDCl₃=1/1, 400 MHz) δ 7.16 (d, J=8.5 Hz, 2H), 6.90 (d,J=8.5 Hz, 2H), 5.01 (d, J=3.7 Hz, 1H), 4.58-4.66 (m, 1H), 4.32 (m, 1H),4.03 (d, J=2.6 Hz, 1H), 3.99 (dd, J=10.6, 4.8, 1H), 3.88-3.96 (m, 2H),3.78-3.88 (m, 4H), 3.62-3.73 (m, 2H), 2.64 (t, J=7.6 Hz, 2H), 2.32 (t,J=7.4 Hz, 2H), 1.61-1.81 (m, 4H), 1.32-1.52 (m, 44H), 0.99 (t, J=6.8 Hz,3H). ¹³C-NMR (CD₃OD/CDCl₃=1/1, 100 MHz) δ 174.06, 155.10, 134.52,128.54, 115.33, 99.16, 73.81, 71.25, 70.40, 69.65, 69.62, 69.12, 68.33,66.60, 61.04, 35.75, 35.70, 34.35, 31.53, 31.25, 31.08, 29.09, 29.03,28.97, 28.94, 28.87, 28.85, 28.76, 28.68, 28.59, 25.27, 25.22, 21.96,21.08, 20.88, 13.08. [α]_(D) ²⁵ +36.2 (c 1.0, CH₂Cl₂/CH₃OH: 1/1). HRMS(ESI) calculated for C₄₄H₇₉NO₁₀Na [M+Na]⁺: 804.5602. found: 804.5641.

Synthesis of1-O-(α-D-galactopyranosyl)-2-(11-(3,4-difluorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol (A17)

By the procedure similar to C34, compound A17 (37 mg, 0.049 mmol, 94%)was obtained from A11 (63 mg, 0.052 mmol). The data of A18: mp: 140° C.¹H-NMR (CD₃OD/CDCl₃=1/1, 400 MHz) δ 7.06-7.22 (m, 2H), 6.98-7.04 (m,1H), 5.03 (d, J=3.3 Hz, 1H), 4.29-4.36 (m, 1H), 4.05 (d, J=2.5 Hz, 1H),4.00 (dd, J=10.5, 4.8, 1H), 3.89-3.96 (m, 2H), 3.78-3.89 (m, 4H),3.64-3.73 (m, 2H), 2.69 (t, J=7.5 Hz, 2H), 2.34 (t, J=7.6 Hz, 2H),1.63-1.83 (m, 4H), 1.33-1.48 (m, 38H), 1.00 (t, J=6.5 Hz, 3H). ¹³C-NMR(CD₃OD/CDCl₃=1/1, 100 MHz) δ 174.07, 149.33 (d, J=247, 13 Hz), 147.95(d, J=244, 13 Hz), 139.47, 123.56, 116.22, 116.06, 99.18, 73.86, 71.82,70.40, 69.67, 69.15, 68.34, 66.63, 61.08, 45.00, 35.78, 35.73, 34.40,31.58, 31.28, 30.66, 29.12, 29.06, 29.00, 28.91, 28.85, 28.77, 28.71,28.44, 25.28, 21.99, 13.12. [α]_(D) ²⁵ +44.4 (c 1.0, CH₂Cl₂/CH₃OH: 1/1).HRMS (ESI) calculated for C₄₁H₇₂F₂NO₉ [M+H]⁺: 760.5175. found: 760.5222.

Synthesis of 1-O-(α-D-galactopyranosyl)-2-(11-(2,4-difluorophenyl)undecanoyl) amino-D-ribo-1,3,4-octadecantriol (A18)

By the procedure similar to C34, compound A18 (39 mg, 0.051 mmol, 88%)was obtained from compound A12 (70 mg, 0.058 mmol). The data of A18: mp:149° C. ¹H-NMR (CD₃OD/CDCl₃=1/1, 400 MHz) δ 7.29 (q, J=8.1 Hz, 1H),6.87-6.97 (m, 2H), 5.05 (d, J=3.7 Hz, 1H), 4.30-4.38 (m, 1H), 4.07 (d,J=2.9 Hz, 1H), 4.03 (dd, J=10.6, 4.4 Hz, 1H), 3.91-3.98 (m, 2H),3.66-3.75 (m, 4H), 3.64-3.73 (m, 2H), 2.73 (t, J=7.5 Hz, 2H), 2.36 (t,J=7.6 Hz, 2H), 1.65-1.86 (m, 4H), 1.24-1.60 (m, 38H), 1.02 (t, J=6.6 Hz,3H). ¹³C-NMR (CD₃OD/CDCl₃=1/1, 100 MHz) δ 174.09, 161.65, 159.20,130.48, 124.73, 110.06, 102.62, 99.19, 73.90, 71.31, 70.40, 69.69,69.17, 68.36, 66.66, 61.11, 50.12, 35.81, 35.76, 31.63, 31.30, 29.59,29.16, 29.14, 29.09, 29.02, 28.92, 28.87, 28.78, 28.76, 28.73, 28.56,27.72, 25.30, 22.01, 13.16. [α]_(D) ²⁵ +46.0 (c 1.0, CH₂Cl₂/CH₃OH: 1/1).HRMS (ESI) calculated for C₄₁H₇₁F₂NO₉Na [M+Na]⁺: 782.4995. found:782.5034.

Synthesis of1-O-(α-D-galactopyranosyl)-2-((10R,11S)-11-(3,4-difluorophenyl)-10,11-dihydroxyundecanoyl)amino-D-ribo-1,3,4-octadecantrioland1-O-(α-D-galactopyranosyl)-2-((10S,11R)-11-(3,4-difluorophenyl)-10,11-dihydroxyundecanoyl)amino-D-ribo-1,3,4-octadecantriol(A19) as a mixture of anti-diol isomers

To the solution of A7 (101 mg, 0.109 mmol) in dichloromethane (3 mL) wasadded anti-B21 (32 mg, 0.097 mmol), HBTU (62 mg, 0.16 mmol) and NMM (24μL, 0.23 mmol). After stirring at room temperature for 12 h, the mixturewas concentrated and the residue was purified by column chromatography(ethyl acetate/n-hexane=1/4 to 1/2 to 1/1). The resulting white wax wasdissolved in dichloromethane/methanol (1/1, 10 mL) and Pd(OH)₂ (10 mg)was then added. After stirring at room temperature under hydrogen for 15h, the mixture was filtered through Celite pad and washed withdichloromethane/methanol (1/1). The filtrate was concentrated and theresidue was purified by column chromatography(dichloromethane/methanol=10/1 then 8/1) to afford A19 (34 mg, 0.043mmol, 44%) as off-white solids. mp: 105° C. ¹H-NMR (CDCl₃/CD₃OD=1/1, 400MHz) δ 7.17-7.40 (m, 3H), 5.01 (d, J=3.6 Hz, 1H), 4.62 (d, J=4.8 Hz,0.75H), 4.50 (d, J=6.0 Hz, 0.25H), 4.28-4.36 (m, 1H), 4.03 (d, J=2.8 Hz,1H), 3.99 (dd, J=4.8, 10.8 Hz, 1H), 3.87-3.95 (m, 2H), 3.76-3.87 (m,4H), 3.61-3.71 (m, 2H), 2.31 (t, J=7.4 Hz, 2H), 1.31-1.83 (m, 40H), 0.99(t, J=6.9 Hz, 3H). ¹³C-NMR (CDCl₃/CD₃OD=1/1, 100 MHz) δ 173.97, 149.42(dd, J=245, 13 Hz), 148.86 (dd, J=245, 13 Hz), 136.65, 122.46, 116.09,115.77, 115.27, 115.10, 99.16, 75.70, 75.35, 74.74, 74.21, 73.94, 71.25,70.40, 69.65, 69.10, 68.31, 66.52, 61.03, 49.91, 35.63, 31.94, 31.69,31.23, 31.18, 29.09, 29.04, 29.00, 28.95, 28.83, 28.76, 28.68, 28.65,28.53, 25.17, 25.08, 24.96, 21.94, 13.04. [α]_(D) ²⁵ +58.3 (c 1.0,CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI) calculated for C₄₁H₇₁F₂NO₁₁Na [M+Na]⁺:814.4893. found: 814.4859.

Synthesis of1-O-(α-D-galactopyranosyl)-2-((10S,11S)-11-(3,4-difluorophenyl)-10,11-dihydroxyundecanoyl)amino-D-ribo-1,3,4-octadecantrioland1-O-(α-D-galactopyranosyl)-2-((10R,11R)-11-(3,4-difluorophenyl)-10,11-dihydroxyundecanoyl)amino-D-ribo-1,3,4-octadecantriol,(A20) as a mixture of syn-diol isomers

To the solution of A7 (101 mg, 0.109 mmol) in dichloromethane (3 mL) wasadded Syn-A21 (14 mg, 0.042 mmol), HBTU (62 mg, 0.16 mmol) and NMM (24μL, 0.22 mmol). After stirring at room temperature for 12 h, the mixturewas concentrated and the residue was purified by column chromatography(ethyl acetate/n-hexane=1/4 to 1/2 to 1/1). The resulting white wax wasdissolved in dichloromethane/methanol (1/1, 10 mL) and Pd(OH)₂ (10 mg)was then added. After stirring at room temperature under hydrogen for 15h, the mixture was filtered through Celite pad and washed withdichloromethane/methanol (1/1). The filtrate was concentrated and theresidue was purified by column chromatography(dichloromethane/methanol=10/1 then 8/1) to afford A20 (20 mg, 0.025mmol, 60%) as white solids. mp: 80° C. ¹H-NMR (CDCl₃/CD₃OD=1/1, 400 MHz)δ 7.19-7.49 (m, 3H), 5.02 (d, J=3.6 Hz, 1H), 4.52 (d, J=6 Hz, 1H),4.30-4.37 (m, 1H), 4.04 (d, J=2.8 Hz, 1H), 4.01 (dd, J=4.4, 10.8 Hz,1H), 3.89-3.96 (m, 2H), 3.78-3.88 (m, 4H), 3.63-3.73 (m, 3H), 2.33 (t,J=7.6 Hz, 2H), 1.26-1.84 (m, 40H), 1.01 (t, J=6.8 Hz, 3H). ¹³C-NMR(CDCl₃/CD₃OD=1/1, 100 MHz) δ 174.00, 149.58 (dd, J=245, 12 Hz), 149.07(dd, J=245, 12 Hz), 138.90, 122.46, 116.13, 115.14, 99.21, 75.47, 74.79,74.01, 71.28, 70.41, 69.69, 69.15, 68.34, 66.57, 61.09, 49.90, 35.67,31.98, 31.77, 31.27, 29.12, 29.03, 28.98, 28.80, 28.68, 28.56, 25.20,25.00, 21.98, 13.08. [α]_(D) ²⁵ +50.0 (c 1.0, CH₂Cl₂/CH₃OH: 1/1). HRMS(ESI) calculated for C₄₁H₇₁F₂NO₁₁Na [M+Na]⁺: 814.4893. found: 814.4893.

Synthesis of1-O-(α-D-galactopyranosyl)-2-(11-(4-bromophenyl)-10,11-dihydroxyundecanoyl)amino-D-ribo-1,3,4-octadecantriol (A21)

By the procedure similar to A19, compound A21 (18 mg, 0.024 mmol, 28%)was obtained from A7 (90 mg, 0.094 mmol) and B19 (32 mg, 0.086 mmol).The data of A21: off-white wax. ¹H-NMR (CD₃OD/CDCl₃=1/1, 400 MHz) δ7.26-7.51 (m, 5H), 5.02-5.10 (m, 1H), 5.02 (d, J=4.0 Hz, 1H), 4.23-4.29(m, 1H), 4.06-4.15 (m, 1H), 3.97-4.03 (m, 2H), 3.83-3.96 (m, 6H), 3.68(t, J=10.2 Hz, 1H), 2.84-2.89 (m, 1H), 2.52 (t, J=7.4 Hz, 2H), 1.27-1.89(m, 40H), 1.02 (t, J=6.8 Hz, 3H). ¹³C-NMR (CD₃OD/CDCl₃=1/1, 150 MHz) δ174.08, 173.54, 138.50, 128.72, 127.55, 125.39, 99.10, 72.40, 71.92,70.84, 70.16, 69.92, 69.57, 69.24, 68.23, 63.43, 61.13, 52.30, 43.34,36.69, 36.39, 35.91, 35.69, 35.26, 33.69, 32.83, 32.03, 31.67, 31.25,30.90, 30.59, 29.81, 29.30, 29.01, 28.97, 28.86, 28.77, 28.67, 28.54,28.46, 25.22, 25.00, 24.36, 24.27, 21.97, 13.09. [α]_(D) ²⁵ +22.7 (c1.0, CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI) calculated for C₄₁H₇₄NO₁₁ [M+H]⁺:778.5081. found: 778.5073.

Scheme 2 Synthesis of Compound A23-25 Synthesis of1-O-(α-D-galactopyranosyl)-2-amino-D-ribo-1,3,4-octadecantriol (A22)

To the solution of A7 (520 mg, 0.545 mmol) in dichloromethane/methanol(1/1, 20 mL) was added Pd(OH)₂ (220 mg) and three drops of acetic acid.The reaction mixture was stirred at room temperature under 80 psihydrogen for 16 h. The mixture was filtered through Celite and thefilter cake was washed with methanol. The filtrate was concentrated anddried in vacuum to afford crude A22 (302 mg, quantitative) as whitesolids. HRMS (ESI) calculated for C₂₄H₄₉NO₈H [M+H]⁺: 480.3536. found:480.3515.

Synthesis of1-O-(α-D-galactopyranosyl)-2-(11-(3,4-dichlorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol (A23)

To the solution of A22 (50 mg, 0.10 mmol) in dichloromethane/methanol(1/1, 3 mL) was added B16 (34 mg, 0.10 mmol), HBTU (59 mg, 0.16 mmol)and NMM (23 μL, 0.21 mmol). The reaction mixture was stirred at roomtemperature for 12 h. The mixture was concentrated and the residue waspurified by column chromatography (dichloromethane/methanol=15/1 to 12/1to 9/1) to afford A23 (16 mg, 0.020 mmol, 20%) as off-white solids. mp:147° C. ¹H-NMR (CD₃OD/CDCl₃=1/1, 400 MHz) δ 7.51 (s, 1H), 7.35 (s, 2H),5.08 (d, J=3.3 Hz, 1H), 4.33-4.43 (m, 1H), 4.08-4.12 (m, 1H), 4.06 (dd,J=10.7, 4.0 Hz, 1H), 3.82-4.02 (m, 6H), 3.67-3.77 (m, 2H), 2.86 (t,J=7.6 Hz, 2H), 2.39 (t, J=7.5 Hz, 2H), 1.66-1.88 (m, 4H), 1.34-1.60 (m,38H), 1.06 (t, J=6.4 Hz, 3H). ¹³C-NMR (CD₃OD/CDCl₃=1/1, 100 MHz) δ174.05, 138.47, 133.89, 131.36, 130.64, 128.41, 126.35, 99.25, 73.99,71.36, 70.42, 69.74, 69.22, 68.42, 66.71, 61.19, 49.97, 35.82, 32.41,31.76, 31.34, 29.20, 29.17, 29.12, 29.06, 28.95, 28.91, 28.81, 28.76,28.69, 25.33, 25.29, 22.06, 13.21. [α]_(D)s+46.8 (c 1.0, CH₂Cl₂/CH₃OH:1/1). HRMS (ESI) calculated for C₄₁H₇₁Cl₂NO₉Na [M+Na]⁺: 814.4404. found:814.4311.

Synthesis of 1-O-(α-D-galactopyranosyl)-2-(11-(4-chlorophenyl)undecanoyl) amino-D-ribo-1,3,4-octadecantriol (A24)

By the procedure similar to A23, compound A24 (18 mg, 0.024 mmol, 22%)was obtained from A22 (52 mg, 0.11 mmol) and B17 (32 mg, 0.11 mmol). Thedata of A24: off-white solids. mp: 136° C. ¹H-NMR (CD₃OD/CDCl₃=1/1, 400MHz) δ 7.28 (d, J=8.4 Hz, 2H), 7.17 (d, J=8.4 Hz, 2H), 4.96 (d, J=3.6Hz, 1H), 4.21-4.29 (m, 1H), 3.98 (d, J=2.5 Hz, 1H), 3.95 (dd, J=10.6,4.4, 1H), 3.83-3.90 (m, 2H), 3.72-3.82 (m, 4H), 3.58-3.68 (m, 2H), 2.64(t, J=7.6 Hz, 2H), 2.28 (t, J=7.8 Hz, 2H), 1.57-1.77 (m, 4H), 1.20-1.51(m, 38H), 0.95 (t, J=6.7 Hz, 3H). ¹³C-NMR (CD₃OD/CDCl₃=1/1, 100 MHz) δ173.99, 140.73, 130.53, 129.08, 127.51, 99.15, 73.79, 71.23, 70.34,69.62, 69.17, 68.32, 66.58, 61.06, 49.87, 35.67, 34.52, 31.53, 31.23,30.73, 29.01, 28.95, 28.87, 28.81, 28.75, 28.65, 28.46, 25.24, 21.94,13.03. [α]_(D) ²⁵ +41.7 (c 1.0, CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI)calculated for C₄₁H₇₂ClNO₉Na [M+Na]⁺: 780.4793. found: 780.4779.

Synthesis of 1-O-(α-D-galactopyranosyl)-2-(11-(4-bromophenyl)undecanoyl) amino-D-ribo-1,3,4-octadecantriol (A25)

By the procedure similar to A23, compound A25 (22 mg, 0.027 mmol, 25%)was obtained from A22 (52 mg, 0.11 mmol) and B28 (56 mg, 0.16 mmol). Thedata of A25: off-white wax. ¹H-NMR (CD₃OD/CDCl₃=1/1, 400 MHz) δ 7.28 (d,J=8.4 Hz, 2H), 7.20-7.47 (m, 2H), 5.00 (d, J=3.6 Hz, 1H), 4.28-4.33 (m,1H), 4.02 (d, J=2.8 Hz, 1H), 3.98 (dd, J=10.6, 4.6 Hz, 1H), 3.863-3.94(m, 2H), 3.77-3.87 (m, 4H), 3.62-3.70 (m, 2H), 2.69 (t, J=7.6 Hz, 2H),2.31 (t, J=7.6 Hz, 2H), 1.29-1.81 (m, 42H), 0.98 (t, J=6.6 Hz, 3H).¹³C-NMR (CD₃OD/CDCl₃=1/1, 100 MHz) δ 171.21, 141.18, 130.44, 129.44,118.39, 99.41, 74.54, 70.41, 70.13, 69.58, 69.50, 69.07, 68.41, 67.22,60.95, 49.68, 35.58, 34.51, 31.36, 31.18, 30.62, 28.95, 28.90, 28.81,28.76, 28.68, 28.61, 28.40, 27.00, 25.21, 24.88, 21.89, 19.90, 19.74,19.57, 12.96. [α]_(D) ²⁵ +40.7 (c 1.0, CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI)calculated for C₄₁H₇₃BrNO₉ [M+H]⁺: 802.4469. found: 802.4216.

(3) Synthetic Scheme 3 Synthesis of Aryl-Alkanoic Acid Synthesis of(9-carboxynonyl)triphenylphosphonium bromide (B2)

10-Bromodecanoic acid (19.65 g, 78.24 mmol) and triphenylphosphine(21.45 g, 81.78 mmol) were mixed and stirred at 150° C. for 24 h. Wittigreagent B2 as light yellow syrup was obtained in 100% yield and usedwithout further purification.

Synthesis of 11-(4-(4-fluorophenoxy)phenyl))undecanoic acid (B4)

To the mixture of B2 (19.89 g, 38.81 mmol) and THF (150 mL) was addedpotassium t-butoxide (10.40 g, 92.68 mmol) at 0° C. The reaction mixturebecame a red solution. The reaction mixture was warmed to rt and stirredfor 1 h. 4-(4-fluorophenoxy)benzaldehyde (B1) (7.50 g, 34.7 mmol) wasadded to the reaction mixture at 0° C. and was stirred for an additional30 min at rt. The reaction mixture was neutralized with 1.0 N HCl andconcentrated. The residue was partitioned with ethyl acetate (200 mL),water (200 mL) (pH value was adjusted to 5 by adding 1.0 N HCl) andbrine (200 mL). The organic phase was isolated and concentrated underreduced pressure. The residue was recrystallized with ethanol/water(1/1, 80 mL) and washed with water to afford B3 (9.99 g, 27.0 mmol, 78%)as white solids. B3 was dissolved in ethanol/ethyl acetate (1/1, 80 mL)and Pd/C (10%, 1.08 g) was added after then. The mixture was stirred atroom temperature under hydrogen for 12 h. The reaction mixture wasfiltered through Celite pad and washed with ethyl acetate. The filtratewas concentrated and recrystallized with methanol/water (5/1, 12 mL),filtered and washed with water to afford 11-(4-(4-fluorophenoxy)phenyl))undecanoic acid (B4) (9.080 g, 24.38 mmol, 90%) as white solids.mp: 73° C. ¹H-NMR (CDCl₃, 400 MHz) δ 6.85-7.13 (m, 8H), 2.56 (t, J=7.6Hz, 2H), 2.33 (t, J=7.4 Hz, 2H), 1.22-1.65 (m, 16H). ¹³C-NMR (CDCl₃, 100MHz) δ 179.69, 159.78, 157.38, 155.36, 153.39, 137.88, 129.56, 120.09,120.01, 118.33, 116.25, 116.02, 35.18, 33.97, 31.59, 29.69, 29.48,29.44, 29.38, 29.24, 29.20, 29.03, 24.65. HRMS (ESI) calculated forC₂₃H₂₉FO₃Na [M+Na]⁺: 395.1998. found: 395.2003.

Synthesis of 11-(4-phenoxy)phenylundecanoic acid (B12)

Similar to the route for compound B4, compound B12 (1.34 g, 3.78 mmol,97%) was synthesized from B2 (3.47 g, 6.76 mmol) and4-phenoxybenzaldehyde (1.03 g, 5.20 mmol). Data for compound B12:off-white solids, mp: 55° C. ¹H-NMR (CDCl₃, 400 MHz) δ 6.93-7.35 (m,9H), 2.60 (t, J=7.4 Hz, 2H), 2.37 (t, J=7.3 Hz, 2H), 1.65 (m, 4H), 1.33(m, 12H). ¹³C-NMR (CDCl₃, 100 MHz) 180.35, 157.71, 154.83, 137.87,130.13, 129.51, 122.73, 118.97, 118.32, 35.18, 34.10, 31.55, 29.45,29.42, 29.36, 29.22, 29.18, 29.00, 24.63. HRMS (ESI) calculated forC₂₃H₃₀O₃Na [M+Na]⁺: 377.2093. found: 377.2053.

Synthesis of 11-(4-isopropoxy)phenylundecanoic acid (B13)

By the similar procedure of synthesis of B4, compound B2 (2.25 g, 4.38mmol) and 4-isopropoxybenzaldehyde (479 mg, 2.92 mmole) were used asstarting materials to afford compound B13 (562 mg, 1.75 mmol, 60%) aswhite solids. mp: 46° C. ¹H-NMR (CDCl₃, 400 MHz) δ 7.04 (d, J=8.5 Hz,2H), 6.78 (d, J=8.6 Hz, 2H), 4.48 (m, 1H), 2.50 (t, J=7.5 Hz, 2H), 2.32(t, J=7.5 Hz, 2H), 1.50-1.61 (m, 4H), 1.25-1.35 (m, 18H). ¹³C-NMR(CDCl₃, 100 MHz) δ 179.73, 155.82, 134.93, 129.20, 115.77, 69.91, 35.04,34.11, 31.69, 29.50, 29.47, 29.40, 29.26, 29.22, 29.12, 29.06, 24.71,22.11, 21.88. HRMS (ESI) calculated for C₂₀H₃₂O₃Na [M+Na]⁺: 343.2249.found: 343.2227.

Synthesis of (10E or 10Z))-1-(3,4-difluorophenyl)undec-10-enoic acid((E)-B7, and (Z)-B7)

By the similar procedure to compound B3, B2 (12.93 g, 25.18 mmol) andTHF (80 mL) and 3,4-difluorobenzaldehyde (2.35 g, 16.5 mmol) werestarting materials to give compound B7 (3.77 g, 12.7 mmol, 77%). TheZ-form and E-form products were separated by recrystallization withn-hexane. (E)-B7 was obtained as white solids. mp: 66° C. ¹H-NMR (CDCl₃,400 MHz) δ 6.98-7.14 (m, 3H), 6.25 (d, J=15.8 Hz, 1H), 6.12 (m, 1H),2.33 (t, J=7.5 Hz, 2H), 2.16 (q, J=7.0 Hz, 2H), 1.61 (m, 2H), 1.43 (m,2H), 1.30 (s, 8H). ¹³C-NMR (CDCl₃, 100 MHz) δ 180.57, 150.49 (dd, J=246,12 Hz), 149.31 (dd, J=241, 13 Hz), 135.29, 132.35, 127.88, 121.99,117.13, 114.18, 34.15, 32.91, 29.31, 29.22, 29.18, 29.08, 24.70. HRMS(ESI) calculated for C₁₇H₂₂F₂O₂Na [M+Na]⁺: 319.1486. found: 319.1485.(Z)-B7 was obtained as colorless oil with 25% inseparable (E)-B7.

Synthesis of (3,4-difluorophenyl)undecanoic acid (B14)

Compound B7 (1.61 g, 5.43 mmol) was dissolved in ethanol/ethyl acetate(1/1, 30 mL) and Pd/C (10%, 160 mg) was added to the solution. Themixture stirred at room temperature under hydrogen for 12 h. The mixturewas filtered through Celite pad and washed with ethyl acetate. Thefiltrate was concentrated and dried in vacuum. Compound B14 was obtainedas white solids (1.61 g, 5.40 mmol, 99%). mp: 51° C. ¹H-NMR (CDCl₃, 400MHz) δ 6.90-7.03 (m, 2H), 6.84 (m, 1H), 2.53 (t, J=7.7 Hz, 2H), 2.33 (t,J=7.5 Hz, 2H), 1.52-1.64 (m, 4H), 1.26 (m, 12H). ¹³C-NMR (CDCl₃, 100MHz) δ 180.24, 150.13 (dd, J=13, 247 Hz), 148.49 (dd, J=13, 246 Hz),147.40, 139.77, 124.05, 116.85, 35.09, 34.01, 31.23, 29.43, 29.36,29.35, 29.18, 29.05, 29.01, 24.64. HRMS (ESI) calculated forC₁₇H₂₄F₂O₂Na [M+Na]⁺: 321.1642. found: 321.1594.

Synthesis of 11-(2,4-difluorophenyl)undecanoic acid (B15)

By the similar procedure of synthesis of B4, compound B2 (2.76 g, 5.38mmol) and 2,4-difluorobenzaldehyde (588 mg, 4.14 mmole) were used asstarting materials to afford compound B15 (431 mg, 1.45 mmol, 35%) asoff-white solids. mp: 56° C. ¹H-NMR (CDCl₃, 400 MHz) δ 7.05-7.13 (m,1H), 6.70-6.79 (m, 2H), 2.66 (t, J=7.6 Hz, 2H), 2.31 (t, J=7.4 Hz, 2H),1.50-1.62 (m, 4H), 1.26 (m, 12H). ¹³C-NMR (CDCl₃, 100 MHz) δ 180.00,162.19, 159.80, 130.90, 125.31, 110.69, 103.44, 34.11, 30.15, 29.44,29.36, 29.33, 29.19, 29.16, 29.03, 28.41, 24.69. HRMS (ESI) calculatedfor C₁₇H₂₄F₂O₂Na [M+Na]⁺: 321.1642. found: 321.1637.

Synthesis of 11-(2,4-dichlorophenyl)undecanoic acid (B16)

By the similar procedure of compound B7, B2 (2.25 g, 4.38 mmol) and2,4-dichlorobenzaldehyde (500 mg, 2.86 mmol) were used as startingmaterials to afford (10E or 10Z))-1-(2,4-dichlorophenyl)undec-10-enoicacid (B9) (576 mg, 1.75 mmol, 61%). Then this compound (210 mg, 0.638mmol) was dissolved in ethyl acetate (10 mL) and Pd/BaSO₄ (21 mg) wasthen added. The mixture was stirred at room temperature under hydrogenfor 12 h. The mixture was filtered through Celite pad and washed withethyl acetate. The combined filtrate was concentrated and dried invacuum to afford compound B16 (210 mg, 0.634 mmol, 99%) as white solids.mp: 78° C. ¹H-NMR (CDCl₃, 400 MHz) δ 7.32 (d, J=1.9 Hz, 1H), 7.09-7.15(m, 2H), 2.65 (t, J=7.8 Hz, 2H), 2.33 (t, J=7.5 Hz, 2H), 1.53-1.63 (m,4H), 1.26 (m, 12H). ¹³C-NMR (CDCl₃, 100 MHz) δ 180.00, 162.19, 159.80,130.90, 125.31, 110.69, 103.44, 34.11, 30.15, 29.44, 29.36, 29.33,29.19, 29.16, 29.03, 28.41, 24.69. HRMS (ESI) calculated forC₁₇H₂₄Cl₂O₂Na [M+Na]⁺: 353.1051. found: 353.1046.

Synthesis of 11-(4-Chlorophenyl)undecanoic acid (B17)

By the similar procedure of synthesis of B10, compound B2 (2.20 g, 4.28mmol) and 4-chlorobenzaldehyde (401 mg, 2.85 mmole) were used asstarting materials to afford B17 (526 mg, 1.77 mmol, 62%). mp: 93° C.¹H-NMR (CDCl₃, 400 MHz) δ 7.21 (d, J=8.4 Hz, 1H), 7.08 (d, J=8.4 Hz,2H), 2.54 (t, J=7.5 Hz, 2H), 2.33 (t, J=7.5 Hz, 2H), 1.53-1.63 (m, 4H),1.26 (m, 12H). ¹³C-NMR (CDCl₃, 100 MHz) δ 179.90, 141.28, 131.21,129.71, 128.27, 35.26, 34.00, 31.35, 29.69, 29.44, 29.39, 29.36, 29.19,29.13, 29.01, 24.64. HRMS (ESI) calculated for C₁₇H₂₅ClO₂Na [M+Na]⁺:319.1441. found: 319.1435.

Synthesis of 11-(4-bromophenyl)undecanoic acid (B18)

By the similar procedure of synthesis of B10, compound B2 (330 mg, 0.643mmol) and 4-bromobenzaldehyde (91.5 mg, 0.495 mmole) were used asstarting materials to afford B18 (98.0 mg, 0.287 mmol, 58%) as off-whitesolids. mp: 91° C. ¹H-NMR (CDCl₃, 400 MHz) δ 7.37 (d, J=8.3 Hz, 1H),7.02 (d, J=8.3 Hz, 2H), 2.53 (t, J=7.6 Hz, 2H), 2.34 (t, J=7.5 Hz, 2H),1.52-1.63 (m, 4H), 1.20-1.37 (m, 12H). ¹³C-NMR (CDCl₃, 100 MHz) δ179.94, 141.79, 141.79, 131.22, 130.14, 119.22, 35.31, 34.11, 31.27,29.44, 29.38, 29.36, 29.19, 29.12, 29.03, 24.68. HRMS (ESI) calculatedC₁₇H₂₆BrO₂ [M+H]⁺: 341.1116. found: 341.1111.

11-(4-bromophenyl)-10,11-dihydroxyundecanoic acid (B20)

To the solution of B11 (389 mg, 1.15 mmol) in t-butanol/water (4/3, 35mL) was added NMO (462 mg, 3.94 mmol) and osmium tetroxide (2.5 wt % int-BuOH, 170 μL, 0.167 mmol). After stirred at room temperature for 15 h,the reaction was quenched with sat. Na₂S₂O₃ and concentrated. Theresidue was partitioned with dichloromethane (50 mL) and sat. Na₂S₂O₃(50 mL). The organic phase was washed with brine (50 mL), concentratedand purified by column chromatography (ethyl acetate/n-hexane=1/2 then1/1) to afford B20 (256 mg, 0.686 mmol, 60%). ¹H-NMR (CD₃OD/CDCl₃=1/1,400 MHz) δ 7.49-7.56 (m, 2H), 7.28-7.37 (m, 2H), 4.59 (d, J=5.1 Hz,0.7H), 4.44 (d, J=6.6 Hz, 0.3H), 3.71-3.77 (m, 0.7H), 3.62-3.66 (m,0.3H), 2.45 (t, J=7.2 Hz, 2H), 1.27-1.78 (m, 14H). ¹³C-NMR(CD₃OD/CDCl₃=1/1, 100 MHz) δ 169.05, 140.40, 140.16, 130.60, 130.30,128.18, 120.64, 120.27, 76.44, 75.80, 74.81, 74.27, 31.88, 30.94, 28.92,28.78, 28.67, 28.63, 28.56, 28.48, 28.45, 28.38, 25.10, 24.88, 24.28.HRMS (ESI) calculated for C₁₇H₂₅BrO₄Na [M+Na]⁺: 395.0834. found:395.0813.

Synthesis of L-(−)-Menthyl (10E)-11-(3,4-difluorophenyl)-undec-10-enoate(Menthyl (E)-B7)

To the solution of (E)-B7 (298 mg, 1.01 mmol) in dichloromethane (3 mL)was added L-(−)-menthol (314 mg, 2.01 mmol), EDC*HCl (347 mg, 1.81 mmol)and DMAP (1.2 mg, 0.010 mmol). The reaction mixture was stirred at roomtemperature for 12 h. The mixture was diluted with dichloromethane (20mL), washed with water (20 mL) and concentrated. The residue waspurified by column chromatography (ethyl acetate/n-hexane=1/50) toafford Menthyl (E)-B7 (112 mg, 0.258 mmol, 26%) as colorless oil. ¹H-NMR(CDCl₃, 400 MHz) δ 6.95-7.13 (m, 3H), 6.24 (d, J=15.6 Hz, 1H), 6.15-6.24(m, 1H), 4.11-4.20 (m, 1H), 2.27 (t, J=7.6 Hz, 2H), 2.15 (q, J=6.8 Hz,2H), 1.92-1.99 (m, 1H), 1.80-1.89 (m, 1H), 1.55-1.68 (m, 4H), 1.38-1.50(m, 3H), 1.22-1.35 (m, 10H), 0.77-1.09 (m, 9H), 0.73 (d, J=7.0 Hz, 3H).¹³C-NMR (CDCl₃, 100 MHz) δ 173.34, 150.39 (dd, J=245, 13 Hz), 149.23(dd, J=246, 13 Hz), 135.15, 132.24, 127.77, 121.87, 117.00, 114.08,73.82, 47.00, 40.93, 34.67, 34.25, 32.82, 31.33, 29.67, 29.26, 29.14,29.08, 29.06, 26.22, 25.06, 23.39, 21.97, 20.70, 16.25. HRMS (ESI)calculated for C₂₇H₄₀F₂O₂Na [M+Na]⁺: 457.2894. found: 457.2863.

Synthesis of (10S,11S)-11-(3,4-difluorophenyl)-10,11-dihydroxyundecanoicacid and (10R,11R)-11-(3,4-difluorophenyl)-10,11-dihydroxyundecanoicacid, syn-(B21) as a mixture of syn-diol isomers

To the solution of menthyl (E)-B7 (110 mg, 0.253 mmol) int-butanol/water (2/1, 6 mL) was added NMO (103 mg, 0.879 mmol) andosmium tetroxide (2.5 wt % in t-BuOH, 38 μL, 0.0037 mmol). Afterstirring at room temperature for 20 h, the reaction mixture was quenchedwith sat. Na₂S₂O₃ (10 mL). The mixture was concentrated and the residuewas dissolved in ethyl acetate (20 mL), washed with sat. Na₂S₂O₃ (20mL), and brine (20 mL), dried over MgSO₄, filtered and concentrated. Theresidue was purified by column chromatography (ethylacetate/n-hexane=1/4 then 1/3). The resulting colorless oil wasdissolved in methanol (5 mL) and 1.0 N NaOH (5 mL) was then added. Afterstirring at room temperature for 12 h, the reaction mixture wasneutralized with 1.0 N HCl (5 mL) and concentrated. The residue waspurified by column chromatography (ethyl acetate/n-hexane=1/2 then 1/1)to afford syn-B21 (35 mg, 0.11 mmol, 43%) as white solids. mp: 104° C.¹H-NMR (CD₃OD, 400 MHz) δ 6.99-7.25 (m, 3H), 4.36 (d, J=5.6 Hz, 1H),3.45-3.52 (m, 1H), 2.18 (t, J=7.4 Hz, 2H), 1.11-1.54 (m, 14H). ¹³C-NMR(CD₃OD, 100 MHz) δ 177.70, 151.29 (dd, J=244, 12 Hz), 150.76 (dd, J=244,13 Hz), 141.48, 124.36, 117.64, 116.87, 77.23, 76.39, 34.39, 33.72,30.51, 30.41, 30.27, 30.15, 26.80, 26.03. HRMS (ESI) calculated forC₁₇H₂₄F₂O₄Na [M+Na]⁺: 353.1540. found: 353.1550.

Synthesis of (10R,11S)— and(10S,11R)-11-(3,4-difluorophenyl)-(10,11)-dihydroxyundecanoic acid,Anti-(B21) as a mixture of anti-diol isomers

To the solution of (Z)-B7 (361 mg, 1.22 mmol) in t-butanol/water (2/1, 6mL) was added NMO (494 mg, 4.22 mmol) and osmium tetroxide (2.5 wt % int-BuOH, 186 μL, 0.0183 mmol). After stirring at room temperature for 20h, the reaction mixture was quenched with sat. Na₂S₂O₃ (15 mL). Themixture was concentrated and the residue was dissolved in ethyl acetate(50 mL), washed with sat. Na₂S₂O₃ (50 mL), and brine (50 mL), dried overMgSO₄, filtered and concentrated. The residue was purified by columnchromatography (ethyl acetate/n-hexane=1/2 then 1/1) to afford anti-B21(246 mg, 0.745 mmol, 61%, a mixture of anti-diol isomers) as colorlessoil. ¹H-NMR (CD₃OD, 400 MHz) δ 7.03-7.25 (m, 3H), 4.36 (d, J=5.5 Hz,1H), 3.47-3.57 (m, 1H), 2.16-2.22 (m, 2H), 1.18-1.56 (m, 14H). ¹³C-NMR(CD₃OD, 100 MHz) δ 177.73, 151.19 (dd, J=245, 13 Hz), 150.72 (dd, J=245,13 Hz), 141.46, 124.57, 117.49, 117.08, 77.34, 77.25, 76.42, 76.06,34.95, 33.75, 33.50, 30.63, 30.51, 30.44, 30.34, 30.20, 26.83, 26.07.HRMS (ESI) calculated for C₁₇H₂₄F₂O₄Na [M+Na]⁺: 353.1540. found:353.1566.

(4) Synthetic Scheme 4 Synthesis of Compound C5-C7 Synthesis of3,4-di-O-benzyl-1-O-(6-azido-2,3,4-tri-O-benzyl-6-deoxy-α-D-galactopyranosyl)-2-hexacosanoylamino-D-ribo-octadecan-1,3,4-triol(C1)

Compound C1 may be synthesized according to Zhou, X. T. et al. Org Lett2002, 4, 1267-1270. Data for C1: ¹H-NMR (CDCl₃, 400 Hz) δ 7.35-7.21 (m,25H), 5.94 (d, J=6.0 Hz, 1H), 4.95 (d, J=11.4 Hz, 1H), 4.82 (d, J=3.2Hz, 1H), 4.79-4.91 (m, 4H), 4.63-4.55 (m, 3H), 4.37-4.48 (m, 2H),4.18-4.30 (m, 2H), 4.00 (dd, J=3.6, 10.1 Hz, 1H), 3.87-3.81 (m, 7H),3.52-3.50 (m, 1H), 1.78-1.79 (m, 74H), 0.86 (t, J=7.0 Hz, 6H).

Synthesis of1-O-(6-phenylacetamido-6-deoxy-α-D-galactopyranosyl)-2-hexacosanoylamino-D-ribo-octadecan-1,3,4-triol(C5)

To the solution of C1 (24 mg, 0.018 mmol) in THF/water (10/1, 5 mL) wasadded triphenylphosphine (10 mg, 0.038 mmol). After stirring at roomtemperature for 2 days, the mixture was concentrated and dried invacuum. The residue was dissolved in chloroform (3 mL). Phenylaceticacid (3 mg, 0.02 mmol), NMM (5 μL, 0.05 mmol) and HBTU (10 mg, 0.026mmol) were added to this solution. After stirring at room temperaturefor 12 h, the mixture was concentrated and purified by columnchromatography (ethyl acetate/n-hexane=1/8 to 1/6 to 1/4) to givecompound C2. The resulting intermediate of C2 was dissolved indichloromethane/methanol (1/1, 5 mL) and Pd(OH)₂ (5.0 mg) was thenadded. After stirring at room temperature under hydrogen for 15 h, themixture was filtered through Celite pad and washed withdichloromethane/methanol (1/1). The filtrate was concentrated andpurified by column chromatography (dichloromethane/methanol=1/1) toafford C5 (4.0 mg, 0.004 mmol, 22%) as white wax. ¹H-NMR (pyridine-ds,400 Hz) δ 7.24-7.43 (m, 5H), 5.51 (d, J=3.8 Hz, 1H), 4.50-4.67 (m, 2H),4.09-4.51 (m, 8H), 3.89 (s, 2H), 3.82-4.01 (m, 1H), 2.21-2.57 (m, 4H),1.08-1.96 (m, 74H), 0.88 (t, J=6.1 Hz, 6H). ¹³C-NMR (pyridine-ds, 150Hz) δ 173.75, 173.46, 142.53, 129.24, 129.20, 126.75, 101.71, 77.08,72.95, 71.64, 71.34, 70.91, 70.50, 68.82, 51.89, 41.50, 38.77, 37.20,34.81, 32.67, 32.51, 30.78, 30.55, 30.42, 30.39, 30.32, 30.20, 29.99,26.90, 26.79, 23.32, 14.66. [α]_(D) ²⁵ +39.3 (c 1.0, CH₂Cl₂/CH₃OH: 1/1).LRMS (ESI) calculated for C₅₈H₁₀₇N₂O₉ [M+H]⁺: 975.80. found: 975.67.

Synthesis of1-O-(6-(3-phenylpropylamido)-6-deoxy-α-D-galactopyranosyl)-2-hexacosanoylamino-D-ribo-octadecan-1,3,4-triol(C6)

By the similar procedure of synthesis of C5, compound C1 (24 mg, 0.018mmol) and 3-phenylpropanoic acid (2.2 mg, 0.018 mmole) were used asstarting materials to afford C6 (10 mg, 0.010 mmol, 55%). ¹H-NMR(pyridine-ds, 400 Hz) δ 7.29-7.30 (m, 5H), 5.50 (d, J=3.7 Hz, 1H),5.20-5.30 (m, 1H), 4.56-4.65 (m, 2H), 4.48 (t, J=6.6 Hz, 1H), 4.25-4.38(m, 5H), 4.15-4.23 (m, 1H), 3.86-3.95 (m, 1H), 3.17-3.26 (m, 2H),2.74-2.89 (m, 2H), 2.41-2.55 (m, 2H), 1.08-2.04 (m, 74H), 0.89 (t, J=6.7Hz, 3H). ¹³C-NMR (pyridine-ds, 400 Hz) δ 173.81, 173.52, 149.78, 142.60,129.32, 129.27, 126.83, 101.78, 77.15, 73.00, 71.70, 71.41, 70.98,70.56, 68.88, 51.94, 38.84, 37.26, 34.88, 32.74, 32.58, 30.86, 30.63,20.50, 30.47, 30.39, 26.97, 26.87, 23.40, 14.74. [α]_(D) ²⁵ +36.0 (c1.0, CH₂Cl₂/CH₃OH: 1/1). LRMS (ESI) calculated for C₅₉H₁₀₉N₂O₉ [M+H]⁺:989.81. found: 989.60.

Synthesis of1-O-(6-(4-phenylbutylamido)-6-deoxy-α-D-galactopyranosyl)-2-hexacosanoylamino-D-ribo-octadecan-1,3,4-triol(C7)

By the similar procedure of synthesis of C5 compound C1 (24 mg, 0.018mmol) and 4-phenylbutanoic acid (2.0 mg, 0.018 mmole) were used asstarting materials to afford C7 (9.0 mg, 0.090 mmol, 50%). ¹H-NMR(pyridine-ds, 400 Hz) 37.27-7.40 (m, 5H), 5.50 (d, J=3.7 Hz, 1H),5.21-5.27 (m, 1H), 4.55-4.66 (m, 2H), 4.48 (t, J=6.6 Hz, 1H), 4.25-4.37(m, 6H), 4.15-4.23 (m, 1H), 3.87-3.95 (m, 1H), 3.16-3.25 (m, 2H),2.74-2.89 (m, 2H), 2.41-2.55 (m, 2H), 1.02-1.98 (m, 74H), 0.88 (t, J=7.2Hz, 6H). ¹³C-NMR (pyridine-ds, 400 Hz) δ 173.30, 173.02, 142.07, 128.82,128.70, 126.33, 101.28, 76.66, 72.50, 71.19, 70.90, 70.48, 70.05, 68.39,51.44, 41.06, 38.34, 36.77, 34.38, 32.25, 32.10, 30.37, 30.13, 30.01,29.98, 29.91, 29.79, 29.76, 29.59, 29.58, 26.47, 26.37, 22.91, 14.25.[α]_(D) ²⁵ +36.9 (c 1.0, CH₂Cl₂/CH₃OH: 1/1). LRMS (ESI) calculated forC₆₀H₁₁₁N₂O₉ [M+H]⁺: 1003.83. found: 1003.47.

(5) Synthetic Scheme 5: Synthesis of Compound C20-C31 Synthesis of1-O-(6-O-toluenesulfonyl-α-D-galactopyranosyl)-2-(11-(3,4-difluorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol(C17)

To the solution of A15 (2.58 g, 3.40 mmol) in pyridine (30 mL) was addedthe solution of p-toluenesulfonyl chloride (712 mg, 3.74 mmol) inpyridine (20 mL) in an ice bath. The reaction mixture was returned tort. After stirring for 16 h, the solvent was evaporated and the residuewas purified by column chromatography (dichloromethane/methanol=100/1 to50/1 to 20/1 to 15/1) to afford C17 as yellow wax (782 mg, 0.855 mmol,25%, 100% BRSM with 2.01 g starting material recovery). ¹H-NMR(CD₃OD/CDCl₃=1/1, 400 MHz) δ 7.96 (d, J=8.3 Hz, 2H), 7.56 (d, J=8.1 Hz,2H), 7.10-7.27 (m, 2H), 7.02-7.09 (m, 1H), 5.01 (d, J=3.2 Hz, 1H),4.29-4.42 (m, 3H), 4.21 (t, J=5.9 Hz, 1H), 3.96-4.04 (m, 2H), 3.85-3.95(m, 2H), 3.81 (dd, J=4.0, 10.6 Hz, 1H), 3.70-3.76 (m, 2H), 2.74 (t,J=7.6 Hz, 2H), 2.62 (s, 3H), 2.35-2.43 (m, 2H), 1.67-1.88 (m, 4H),1.36-1.60 (m, 38H), 1.05 (t, J=6.7 Hz, 3H). ¹³C-NMR (CD₃OD/CDCl₃=1/1,100 MHz) δ 173.84, 149.47 (dd, J=246, 13 Hz), 148.00 (dd, J=244, 13 Hz),144.74, 139.43, 132.04, 129.32, 127.44, 123.60, 116.22, 114.55, 99.09,73.87, 71.39, 69.27, 68.98, 68.51, 68.15, 68.07, 66.95, 35.85, 34.46,31.71, 31.34, 30.72, 29.21, 29.17, 29.12, 29.06, 28.96, 28.91, 28.82,28.77, 28.50, 25.30, 22.06, 20.67, 13.22. HRMS (ESI) calculated forC₄₈H₇₈F₂NO₁₁S [M+H]⁺: 914.5264. found: 914.5228.

Synthesis of1-O-(6-azido-6-deoxy-α-D-galactopyranosyl)-2-(11-(3,4-difluorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol(C18)

To the solution of C17 (1.63 g, 1.78 mmol) in DMF (15 mL) was addedsodium azide (322 mg, 4.95 mmol). The reaction mixture was stirred at100° C. for 2 days. The mixture was concentrated and the residue waspurified by column chromatography (dichloromethane/methanol=20/1 to15/1) to afford crude C18 (1.15 g, 1.47 mmol, 82%) as yellow solids. mp:101° C. ¹H-NMR (CD₃OD/CDCl₃=1/1, 400 MHz) δ 7.25-7.51 (m, 3H), 5.36 (d,J=3.2 Hz, 1H), 4.57-4.67 (m, 1H), 4.12-4.42 (m, 6H), 3.94-4.06 (m, 3H),3.74 (dd, J=12.8, 4.8 Hz, 1H), 3.00 (t, J=7.7 Hz, 2H), 2.60-2.67 (m,2H), 1.62-2.15 (m, 42H), 1.32 (t, J=6.8 Hz, 3H). HRMS (ESI) calculatedfor C₄₁H₇₁F₂N₄O₈[M+H]⁺: 785.5240. found: 785.5267.

Synthesis of1-O-(6-amino-6-deoxy-α-D-galactopyranosyl)-2-(11-(3,4-difluorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol(C19)

The solution of C18 (1.11 g, 1.41 mmol) in THF/water (10/1, 33 mL) wasadded triphenylphosphine (0.74 g, 2.8 mmol). The reaction mixture wasstirred at room temperature for 2 days. The mixture was concentrated andthe residue was purified by column chromatography (1% triethylamine,dichloromethane/methanol=6/1 to 4/1 to 2/1) to afford C19 (566 mg, 0.746mmol, 53%) as white solids. mp: 161° C. ¹H-NMR (CD₃OD, 400 MHz) δ6.95-7.09 (m, 2H), 6.86-6.88 (m, 1H), 4.82 (d, J=3.2 Hz, 1H), 4.13-4.19(m, 1H), 3.83 (dd, J=10.4, 4.4 Hz, 1H), 3.75 (d, J=2.0, 1H), 3.63-3.73(m, 3H), 3.59 (dd, J=10.8, 5.6 Hz, 1H), 3.44-3.54 (m, 2H), 2.87 (dd,J=13.2, 7.6 Hz, 1H), 2.72 (dd, J=13.2, 4.4 Hz, 1H), 2.51 (t, J=7.6 Hz,2H), 2.14 (t, J=7.5 Hz, 2H), 1.50-1.63 (m, 4H), 1.16-1.32 (m, 38H), 0.82(t, J=6.8 Hz, 3H). ¹³C-NMR (CD₃OD, 100 MHz) δ 176.07, 151.5 (d, J=246,13 Hz), 150.8 (d, J=243, 12 Hz), 141.74, 125.79, 118.16, 118.02, 101.43,75.90, 73.12, 72.46, 72.02, 71.63, 70.33, 68.35, 52.18, 43.44, 37.46,36.20, 33.37, 33.26, 32.68, 31.06, 31.02, 30.96, 30.89, 30.81, 30.73,30.67, 30.62, 30.39, 27.30, 27.21, 23.29. HRMS (ESI) calculated forC₄₁H₇₃F₂N₂O₈[M+H]⁺: 759.5335. found: 759.5319.

Synthesis of1-O-(6-(4-Nitrophenylacetamido)-6-deoxy-α-D-galactopyranosyl)-2-(11-(3,4-difluorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol(C20)

To the solution of C19 (34 mg, 0.045 mmol) in dichloromethane/methanol(1/1, 3 mL) was added 4-nitrophenylacetic acid (8.1 mg, 0.045 mmol),HBTU (34 mg, 0.090 mmol) and NMM (20 μL, 0.18 mmol). After stirring atroom temperature for 16 h, the mixture was concentrated and purified bycolumn chromatography (dichloromethane/methanol=30/1 to 20/1). The crudeproduct was dissolved in dichloromethane/methanol (1/1, 3 mL) andSi-carbonate silica gel (HOBT scavenger, 100 mg) was added to thesolution. After stirring at room temperature for 1 h, the mixture wasfiltered and washed with dichloromethane/methanol (1/1). The filtratewas concentrated and dried in vacuum to afford C20 (13 mg, 0.014 mmol,31%) as light yellow wax. ¹H-NMR (CDCl₃/CD₃OD=1/1, 200 MHz) δ 8.25 (d,J=8.7 Hz, 2H), 7.68 (d, J=8.7 Hz, 2H), 6.90-7.21 (m, 3H), 4.94 (d, J=3.2Hz, 1H), 4.20-4.26 (m, 1H), 3.77-3.92 (m, 5H), 3.58-3.74 (m, 6H), 2.63(t, J=7.4 Hz, 2H), 2.28 (t, J=7.6 Hz, 2H), 1.30-1.81 (m, 42H), 0.98 (t,J=6.8 Hz, 3H). ¹³C-NMR (CDCl₃/CD₃OD=1/1, 50 MHz) δ 173.93, 170.81,149.17 (dd, J=246, 13 Hz), 148.05 (dd, J=244, 13 Hz), 146.43, 142.53,139.35, 129.58, 123.59, 122.95, 116.28, 116.11, 98.99, 73.65, 71.21,69.35, 69.18, 68.41, 68.14, 66.16, 49.81, 41.69, 39.69, 36.34, 35.69,34.36, 31.61, 31.25, 30.66, 29.04, 28.74, 28.41, 25.27, 21.97, 13.07.[α]_(D) ²⁵ +39.3 (c 1.0, CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI) calculated forC₄₉H₇₈F₂N₃O₁₁ [M+H]⁺: 922.5604. found: 922.5629.

Synthesis of1-O-(6-(2,4-dinitrophenylacetamido)-6-deoxy-α-D-galactopyranosyl)-2-(11-(3,4-difluorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol (C21)

By the similar procedure of synthesis of C20, compound C19 (34 mg, 0.045mmol) and 2,4-dinitrophenylacetic acid (10 mg, 0.045 mmole) were used asstarting materials to afford C21 (4.0 mg with inseparable impurities,0.0041 mmol, 9%). ¹H-NMR (CDCl₃/CD₃OD=1/1, 600 MHz) δ 7.39-7.48 (m, 3H),6.97-7.17 (m, 3H), 4.98 (d, J=3.2 Hz, 1H), 4.24-4.31 (m, 1H), 3.59-3.93(m, 10H), 2.65 (t, J=7.4 Hz, 2H), 2.26-2.31 (m, 2H), 1.14-1.87 (m, 42H),0.90-1.02 (m, 3H). ¹³C-NMR (CDCl₃/CD₃OD=1/1, 150 MHz) δ 173.95, 169.65,148.64, 147.80, 139.33, 134.76, 132.72, 129.90, 129.13, 123.53, 123.15,116.92, 116.57, 116.13, 110.69, 99.01, 73.64, 73.42, 71.16, 69.32,69.08, 68.12, 66.07, 49.80, 39.45, 39.60, 38.18, 38.13, 36.30, 35.66,34.33, 34.30, 33.63, 32.01, 31.60, 31.43, 30.67, 30.58, 29.73, 29.23,28.39, 28.35, 28.23, 26.30, 25.23, 25.17, 23.06, 22.25, 22.20, 21.78,12.98. [α]_(D) ²⁵ +47.1 (c 1.0, CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI)calculated for C₄₉H₇₆F₂N₃O₁₃H [M+H]⁺: 967.5455. found: 967.5485.

1-O-(6-(4-tert-Butylphenylacetamido)-6-deoxy-α-D-galactopyranosyl)-2-(11-(3,4-difluorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol(C22)

By the similar procedure of synthesis of C20, compound C19 (34 mg, 0.045mmol) and 4-tert-butylphenylacetic acid (8.6 mg, 0.044 mmole) were usedas starting materials to afford C22 (12 mg, 0.013 mmol, 29%). mp: 170°C. ¹H-NMR (CDCl₃/CD₃OD=1/1, 400 MHz) δ 7.47 (d, J=8.0 Hz, 2H), 7.32 (d,J=8.0 Hz, 2H), 6.98-7.22 (m, 3H), 4.97 (d, J=3.2 Hz, 1H), 4.29-4.34 (m,1H), 3.80-3.95 (m, 5H), 3.76 (dd, J=10.8, 4.4 Hz, 1H), 3.61-3.71 (m,5H), 3.36 (dd, J=7.8, 13.8 Hz, 1H), 2.68 (t, J=7.6 Hz, 2H), 2.33 (t,J=7.6 Hz, 2H), 1.63-1.82 (m, 4H), 1.31-1.53 (m, 47H), 1.00 (t, J=6.5 Hz,3H). ¹³C-NMR (CDCl₃/CD₃OD=1/1, 100 MHz) δ 173.91, 172.88, 149.40 (dd,J=246, 12 Hz), 148.02 (dd, J=243, 13 Hz), 139.36, 131.28, 124.96,123.57, 116.21, 116.05, 99.06, 73.79, 71.30, 69.35, 68.97, 68.40, 68.20,66.42, 49.84, 41.82, 39.39, 35.72, 34.37, 33.66, 31.66, 31.25, 30.65,30.38, 29.14, 29.09, 29.05, 29.03, 28.97, 28.89, 28.83, 28.75, 28.71,28.68, 28.42, 25.28, 25.24, 21.96, 13.06. [α]_(D) ²⁵ +36.4 (c 1.0,CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI) calculated for C₅₃H₈₈F₂N₂O₉[M+H]⁺:933.6380. found: 933.6435.

Synthesis of1-O-(6-(4-bromophenylacetamido)-6-deoxy-α-D-galactopyranosyl)-2-(11-(3,4-difluorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol(C23)

By the similar procedure of synthesis of C20, compound C19 (34 mg, 0.045mmol) and 4-bromophenylacetic acid (9.7 mg, 0.044 mmole) were used asstarting materials to afford C23 (15 mg, 0.016 mmol, 35%) as off-whitesolids. mp=177° C. ¹H-NMR (CDCl₃/CD₃OD=1/1, 400 MHz) δ 7.54 (d, J=8.4Hz, 2H), 7.29 (d, J=8.0 Hz, 2H), 6.97-7.20 (m, 3H), 4.97 (d, J=3.6 Hz,1H), 4.28-4.33 (m, 1H), 3.78-3.92 (m, 5H), 3.59-3.74 (m, 6H), 3.37 (dd,J=7.6, 13.6 Hz, 1H), 2.66 (t, J=7.6 Hz, 2H), 2.31 (t, J=7.6 Hz, 2H),1.30-1.81 (m, 42H), 0.98 (t, J=6.8 Hz, 3H). ¹³C-NMR (CDCl₃/CD₃OD=1/1,100 MHz) δ 173.90, 171.91, 149.53 (dd, J=247, 13 Hz), 147.86 (dd, J=245,12 Hz), 139.35, 133.70, 130.98, 130.29, 123.58, 120.22, 120.22, 116.18,116.02, 99.03, 73.77, 71.26, 69.34, 69.08, 68.38, 68.15, 66.32, 49.81,41.48, 39.51, 35.68, 34.35, 31.63, 31.23, 30.62, 29.11, 29.08, 29.01,28.95, 28.87, 28.81, 28.73, 28.68, 28.66, 28.40, 25.25, 25.22, 21.94,13.03. [α]_(D) ²⁵ +42.3 (c 1.0, CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI)calculated for C₄₉H₇₈BrF₂N₂O₉ [M+H]⁺: 955.4859. found: 955.4920.

Synthesis of1-O-(6-(4-methoxyphenylacetamido)-6-deoxy-α-D-galactopyranosyl)-2-(11-(3,4-difluorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol(C24)

By the similar procedure of synthesis of C20, compound C19 (34 mg, 0.045mmol) and 4-methoxyphenylacetic acid (7.5 mg, 0.045 mmole) were used asstarting materials to afford C24 (15 mg, 0.017 mmol, 38%) as off-whitesolids. mp: 172° C. ¹H-NMR (CDCl₃/CD₃OD=1/1, 400 MHz) δ 7.36 (d, J=8.8Hz, 2H), 7.12-7.26 (m, 2H), 7.01-7.09 (m, 3H), 5.02 (d, J=3.6 Hz, 1H),4.32-4.38 (m, 1H), 3.97 (s, 3H), 3.72-3.96 (m, 5H), 3.69-3.78 (m, 4H),3.65 (s, 2H), 3.40 (dd, J=7.8, 14.0 Hz, 1H), 2.74 (t, J=7.6 Hz, 2H),2.38 (t, J=7.6 Hz, 2H), 1.38-1.89 (m, 42H), 1.05 (t, J=6.8 Hz, 3H).¹³C-NMR (CDCl₃/CD₃OD=1/1, 100 MHz) δ 173.91, 173.06, 149.59 (dd, J=247,13 Hz), 148.08 (dd, J=244, 13 Hz), 158.27, 129.40, 129.66, 126.43,123.61, 116.29, 116.12, 114.55, 113.62, 99.08, 73.92, 71.39, 61.41,69.03, 68.41, 68.24, 66.43, 54.47, 49.78, 41.57, 39.46, 35.82, 34.46,31.80, 31.33, 30.71, 29.22, 29.17, 29.12, 29.11, 29.05, 28.96, 28.90,28.82, 28.78, 28.75, 28.49, 25.34, 25.31, 22.04, 13.19. [α]_(D) ²⁵ +44.3(c 1.0, CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI) calculated for C₅₀H₈₁F₂N₂O₁₀[M+H]⁺: 907.5859. found: 907.5890.

Synthesis of1-O-(6-(3,4-di(trifluoromethyl)phenyl-acetamido)-6-deoxy-α-D-galactopyranosyl)-2-(11-(3,4-ifluorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol (C25)

By the similar procedure of synthesis of C20, compound C19 (34 mg, 0.045mmol) and 3,4-di(trifluroromethanyl)phenylacetic acid (12 mg, 0.045mmole) were used as starting materials to afford C25 (11 mg, 0.011 mmol,24%) as off-white solids. mp: 180° C. ¹H-NMR (CDCl₃/CD₃OD=1/1, 400 MHz)δ 7.98 (s, 2H), 7.91 (s, 1H), 769-7.22 (m, 3H), 5.01 (d, J=3.6 Hz, 1H),4.28-4.33 (m, 1H), 3.84-3.99 (m, 5H), 3.83 (s, 2H), 3.78 (dd, J=4.2,10.8 Hz, 1H), 3.22-3.32 (m, 3H), 3.42-3.51 (m, 1H), 2.69 (t, J=7.6 Hz,2H), 2.33 (t, J=7.4 Hz, 2H), 1.39-1.82 (m, 42H), 1.00 (t, J=6.8 Hz, 3H).(¹³C-NMR CDCl₃/CD₃OD=1/1, 100 MHz) δ 174.04, 170.56, 143.17, 139.37,137.65, 131.13, 130.80, 129.10, 124.18, 123.56, 121.47, 120.09, 116.22,116.06, 114.50, 99.07, 73.77, 71.32, 69.40, 69.27, 68.42, 68.20, 66.30,49.99, 41.14, 39.78, 35.75, 34.39, 31.73, 31.27, 30.66, 29.14, 29.09,29.04, 28.99, 28.88, 28.75, 28.71, 28.69, 28.42, 25.29, 25.24, 21.98,13.08. [α]_(D) ²⁵ +40.1 (c 1.0, CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI)calculated for C₅₁H₇₇F₈N₂O₉[M+H]⁺: 1013.5501. found: 1013.5567.

Synthesis of1-O-(6-(3,4-difluorophenylacetamido)-6-deoxy-α-D-galactopyranosyl)-2-(11-(3,4-difluorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol(C26)

By the similar procedure of synthesis of C20, compound C19 (34 mg, 0.045mmol) and 3,4-difluorophenylacetic acid (7.7 mg, 0.045 mmole) were usedas starting materials to afford C26 (17 mg, 0.019 mmol, 42%) asoff-white solids. mp: 182° C. ¹H-NMR (CDCl₃/CD₃OD=1/1, 400 MHz) δ6.97-7.43 (m, 6H), 4.97 (d, J=3.6 Hz, 1H), 4.28 (q, J=4.4, 9.6 Hz, 1H),3.83-4.01 (m, 4H), 3.80 (dd, J=3.2, 10.0 Hz, 1H), 3.71 (dd, J=4.4, 10.6Hz, 1H), 3.60-3.68 (m, 3H), 3.59 (s, 2H), 3.38 (dd, J=8.0, 13.6 Hz, 1H),2.66 (t, J=7.6 Hz, 2H), 2.30 (t, J=7.6 Hz, 2H), 1.32-1.81 (m, 42H), 0.97(t, J=6.8 Hz, 3H). ¹³C-NMR CDCl₃/CD₃OD=1/1, 100 MHz) δ 173.92, 171.63,150.67, 150.03, 149.13, 148.25, 147.65, 146.72, 139.34, 131.81, 124.72,123.54, 117.52, 117.34, 116.97, 116.59, 116.42, 116.25, 116.08, 115.93,99.02, 73.75, 71.23, 69.34, 69.15, 68.38, 68.14, 66.24, 49.82, 41.06,39.57, 35.66, 34.33, 31.63, 31.23, 30.61, 29.10, 29.07, 29.00, 28.94,28.85, 28.79, 28.71, 28.65, 28.38, 25.24, 25.20, 21.93, 13.01. [α]_(D)²⁵ +53.8 (c 1.0, CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI) calculated forC₄₉H₇₇F₄N₂O₉ [M+H]⁺: 913.5565. found: 913.5606.

Synthesis of1-O-(6-(3-trifluoromethylphenyl-acetamido)-6-deoxy-α-D-galactopyranosyl)-2-(11-(3,4-difluorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol(C27)

By the similar procedure of synthesis of C20, compound C19 (34 mg, 0.045mmol) and 3-trifluoromethylphenylacetic acid (9.2 mg, 0.045 mmole) wereused as starting materials to afford C27 (12 mg, 0.013 mmol, 29%) asoff-white solids. mp: 157° C. ¹H-NMR (CDCl₃/CD₃OD=1/1, 400 MHz) δ6.96-7.82 (m, 7H), 4.96 (d, J=3.6 Hz, 1H), 4.25-4.30 (m, 1H), 4.03-4.10(m, 1H), 3.77-3.91 (m, 5H), 3.53-3.74 (m, 5H), 3.36-3.44 (m, 1H), 2.65(t, J=7.6 Hz, 2H), 2.29 (t, J=7.6 Hz, 2H), 1.27-1.76 (m, 42H), 0.97 (t,J=6.8 Hz, 3H). ¹³C-NMR (CDCl₃/CD₃OD=1/1, 100 MHz) δ 174.52, 172.19,150.04 (dd, J=247, 13 Hz), 148.52 (dd, J=244, 13 Hz), 139.90, 136.43,132.64, 129.02, 127.67, 125.80, 124.17, 116.76, 116.60, 111.27, 99.64,74.33, 71.87, 69.93, 69.73, 68.98, 68.76, 66.90, 60.57, 50.44, 42.27,40.16, 36.25, 34.92, 32.20, 31.82, 31.21, 29.68, 29.65, 29.59, 29.53,29.44, 29.38, 29.30, 29.24, 28.97, 25.83, 25.80, 22.52, 13.60. [α]_(D)²⁵ +47.4 (c 1.0, CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI) calculated forC₅₀H₇₈F₅N₂O₉[M+H]⁺: 945.5627. found: 945.5611.

Synthesis of1-O-(6-(4-methylphenylacetamido)-6-deoxy-α-D-galactopyranosyl)-2-(11-(3,4-difluorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol(C28)

By the similar procedure of synthesis of C20, compound C19 (34 mg, 0.045mmol) and 4-methylphenylacetic acid (6.8 mg, 0.045 mmole) were used asstarting materials to afford C28 (11 mg, 0.012 mmol, 27%) as off-whitesolids. mp: 171° C. ¹H-NMR (CDCl₃/CD₃OD=1/1, 400 MHz) δ 7.28-44 (m, 4H),7.12-7.26 (m, 2H), 7.03-7.08 (m, 1H), 5.01 (d, J=3.6 Hz, 1H), 4.32-4.41(m, 1H), 3.83-3.95 (m, 5H), 3.67-3.79 (m, 3H), 3.66 (s, 2H), 3.40 (dd,J=7.6, 13.6 Hz, 1H), 2.73 (t, J=7.6 Hz, 2H), 2.37 (t, J=7.6 Hz, 2H),1.32-1.87 (m, 42H), 1.05 (t, J=6.8 Hz, 3H). ¹³C-NMR (CDCl₃/CD₃OD=1/1,100 MHz) δ 173.94, 172.96, 149.83 (dd, J=247, 13 Hz), 148.02 (dd, J=244,13 Hz), 139.42, 136.24, 131.26, 128.86, 128.47, 123.42, 116.31, 116.15,99.10, 73.89, 71.43, 69.40, 68.98, 68.41, 68.25, 66.49, 49.82, 42.07,39.42, 35.83, 34.47, 31.78, 31.34, 30.73, 29.23, 29.19, 29.12, 29.06,28.97, 28.92, 28.84, 28.80, 28.77, 28.51, 25.35, 25.32, 22.06, 20.10,13.22. [α]_(D) ²⁵ +31.8 (c 1.0, CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI)calculated for C₅₀H₈₁F₂N₂O₉[M+H]⁺: 891.5910. found: 891.5988.

Synthesis of1-O-(6-(3-methylphenylacetamido)-6-deoxy-α-D-galactopyranosyl)-2-(11-(3,4-difluorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol(C29)

By the similar procedure of synthesis of C20, compound C19 (34 mg, 0.045mmol) and 3-methylphenylacetic acid (6.8 mg, 0.045 mmole) were used asstarting materials to afford C29 (14 mg, 0.016 mmol, 35%) as off-whitesolids. mp: 167° C. ¹H-NMR (CDCl₃/CD₃OD=1/1, 400 MHz) δ 7.18-7.51 (m,7H), 5.08 (d, J=4.0 Hz, 1H), 4.36-4.43 (m, 1H), 3.91-4.02 (m, 5H),3.23-3.35 (m, 4H), 3.73 (s, 2H), 3.47 (dd, J=7.8, 13.8 Hz, 1H), 2.79 (t,J=7.8 Hz, 2H), 2.57 (s, 3H), 2.43 (t, J=7.6 Hz, 2H), 1.46-1.94 (m, 42H),1.11 (t, J=6.8 Hz, 3H). ¹³C-NMR (CDCl₃/CD₃OD=1/1, 100 MHz) δ 173.96,172.85, 149.52 (dd, J=245, 13 Hz), 148.13 (dd, J=243, 13 Hz), 139.43,137.90, 134.27, 129.41, 128.13, 127.37, 125.61, 123.67, 116.35, 116.19,99.15, 73.99, 71.49, 69.44, 69.00, 68.41, 68.30, 66.53, 49.88, 42.50,39.46, 35.89, 34.52, 31.91, 31.39, 30.76, 29.28, 29.23, 29.11, 29.01,28.96, 28.88, 28.84, 28.81, 28.55, 25.38, 25.36, 22.11, 13.29. [α]_(D)²⁵ +36.8 (c 1.0, CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI) calculated forC₅₀H₈₁F₂N₂O₉ [M+H]⁺: 891.5910. found: 891.5950.

Synthesis of1-O-(6-(2-methylphenylacetamido)-6-deoxy-α-D-galactopyranosyl)-2-(11-(3,4-difluorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol(C30)

By the similar procedure of synthesis of C20, compound C19 (34 mg, 0.045mmol) and 2-methylphenylacetic acid (6.8 mg, 0.045 mmole) were used asstarting materials to afford C30 (16 mg, 0.018 mmol, 40%) as off-whitesolids. mp: 182° C. ¹H-NMR (CDCl₃/CD₃OD=1/1, 400 MHz) δ 7.31-7.37 (m,4H), 7.01-7.26 (m, 3H), 4.99 (d, J=3.6 Hz, 1H), 4.30-4.35 (m, 1H),3.83-3.94 (m, 5H), 3.68-3.75 (m, 6H), 3.40 (dd, J=8.0, 13.8 Hz, 1H),2.72 (t, J=7.8 Hz, 2H), 2.45 (s, 3H), 2.36 (t, J=7.6 Hz, 2H), 1.32-1.87(m, 42H), 1.04 (t, J=6.8 Hz, 3H). ¹³C-NMR (CDCl₃/CD₃OD=1/1, 100 MHz) δ173.86, 172.42, 149.48 (dd, J=246, 13 Hz), 147.94 (dd, J=243, 13 Hz),139.41, 136.38, 132.67, 129.91, 129.65, 126.99, 125.79, 123.63, 116.28,116.11, 99.15, 73.91, 71.38, 69.38, 69.11, 68.35, 68.20, 66.56, 49.74,40.27, 39.49, 35.80, 34.45, 31.78, 31.32, 30.70, 29.21, 29.16, 29.10,29.04, 28.95, 28.90, 28.81, 28.77, 28.74, 28.48, 25.33, 25.29, 22.03,18.65, 13.17. [α]_(D) ²⁵ +38.3 (c 1.0, CH₂Cl₂/CH₃OH: 1/1). HRMS (ESI)calculated for C₅₀H₈₁F₂N₂O₉[M+H]⁺: 891.5910. found: 891.5987.

Synthesis of1-O-(6-(2-naphthylacetamido)-6-deoxy-α-D-galactopyranosyl)-2-(11-(3,4-difluorophenyl)undecanoyl)amino-D-ribo-1,3,4-octadecantriol(C31)

By the similar procedure of synthesis of C20, compound C19 (34 mg, 0.045mmol) and 2-naphthylacetic acid (8.4 mg, 0.045 mmole) were used asstarting materials to afford C31 (12 mg, 0.013 mmol, 29%) as whitesolid. mp: 178° C. ¹H-NMR (CDCl₃/CD₃OD=1/1, 400 MHz) δ 7.85-8.04 (m,3H), 7.40-7.69 (m, 4H), 7.05-7.29 (m, 3H), 5.03 (d, J=3.6 Hz, 1H),4.31-4.40 (m, 1H), 3.87-4.01 (m, 6H), 3.72-3.81 (m, 4H), 3.46 (dd,J=7.8, 14.0 Hz, 1H), 2.76 (t, J=7.6 Hz, 2H), 2.38 (t, J=8.0 Hz, 2H),1.32-1.90 (m, 42H), 1.08 (t, J=6.6 Hz, 3H). ¹³C-NMR (CDCl₃/CD₃OD=1/1,150 MHz) δ 173.92, 172.58, 149.54 (dd, J=244, 12 Hz), 147.93 (dd, J=240,13 Hz), 142.73, 139.39, 133.06, 131.96, 127.78, 127.34, 127.01, 126.97,126.48, 125.61, 125.20, 123.60, 123.30, 123.14, 117.04, 116.24, 116.09,110.83, 99.07, 73.85, 71.38, 69.38, 69.05, 68.42, 68.21, 66.45, 49.81,42.35, 39.52, 35.75, 34.41, 31.74, 31.29, 30.67, 29.72, 29.18, 29.13,29.07, 29.01, 28.92, 28.68, 28.78, 28.72, 28.45, 25.30, 25.28, 22.00,13.12. [α]_(D) ²⁵ +8.3 (c 1.0, CH₂Cl₂/CH₃OH: 1/1).

Synthesis of compounds of formula (1)

A number of glycosphingolipids were synthesized and tested for NKT cellactivation. Compounds' structures are according to formula 1.

wherein compound No. (R) is selected from Table 1 to provide thecorresponding compounds.

TABLE 1 Compound structure. Compound no., R=

A15: X = OPh, Y = H, Z = H A16: X = O-i-Pr, Y = H, Z = H A17: X = F, Y =F, Z = H A18: X = F, Y = H, Z = F A23: X = Cl, Y = H, Z = Cl A24: X =Cl, Y = H, Z = H A25: X = Br, Y = H, Z = H A26: X = F, Y = F, Z = H A27:X = NO2, Y = H, Z = H A28: X = N(CH3)2, Y = H, Z = H A29: X = F, Y =CF3, Z = H A30: X = i-Pr, Y = H, Z = H A31: X = 2-(5-F)-pyridine, Y = H,Z = H C34: X = OPh(4-F), Y = H, Z = H

C4: n = 1 C5: n = 2 C6: n = 3

C20: X = NO2, Y = H, Z = H C21: X = NO2, Y = H, Z = NO2 C22: X = t-Bu, Y= H, Z = H C23: X = Br, Y = H, Z = H C24: X = OMe, Y = H, Z = H C25: X =CF3, Y = CF3, Z = H C26: X = F, Y = F, Z = H C27: X = H, Y = CF3, Z = HC28: X = H, Y = H, Z = Me C29: X = H, Y = Me, Z = H C30: X = Me, Y = H,Z = H

C31

A32         A33

 

A34

A35

A36

A37

A38

A19, A20

A21

A39

Example 2 Antigen Presenting Cell (APC) Activation

A20CD1d cells and mNK1.2 cells were used as APC and effector cells,respectively. Guava ViaCount reagent was used to determine the viabilityand viable number of cells with Guava EasyCyte Plus. Mouse IL-2 DuoSetELISA Development System was used to detect the production of IL-2.Cells and glycolipids were co-cultured at 37° C. and supernatant wascollected at 24 h after culture. And, two days after culture, cells wereharvested to determine the viability and the results show that theseglycospingolipids are not toxic. As shown in FIG. 6, in this connection,all of test compounds exhibit APC activation activities.

IFN-γ and Il-4 Cytokine Secretions

Female C57BL/6 mouse (16w4d) was sacrificed and spleen was harvested forthe assay. Cells and glycolipids were coculture at 37° C. for 3 days andsupernatant was collected at 3rd day (˜60 h) after culture. Then, alarmaBlue (5%/200 ul) was added and cells were cultured for 7 h to determinethe cell proliferation. Mouse IL-4 and IFN-γ Duo Set ELISA DevelopmentSystem was used to detect the cytokine production. In this assay DMSOwas negative control and KRN-7000 was positive control. As shown in theFIG. 7-9, compounds have shown Th1-biased cytokine secretion profile,indicating their applicability for antitumor, antiviral/antibacterial,and adjuvant activities.

All publications and patent applications cited in this specification areherein incorporated by reference as if each individual publication orpatent application were specifically and individually indicated to beincorporated by reference.

Although the foregoing invention has been described in some detail byway of illustration and example for purposes of clarity ofunderstanding, it will be readily apparent to those of ordinary skill inthe art in light of the teachings of this invention that certain changesand modifications may be made thereto without departing from the spiritor scope of the appended claim

What is claimed is:
 1. A method for preparing a chiral compoundcomprising an R-form or S-form of a compound of formula (5):

or a pharmaceutically acceptable salt thereof, via alpha-glycosylation,the method comprising reacting a compound of formula (6):

or pharmaceutically acceptable salt thereof, wherein PG is a hydroxylprotecting group and LG is the following:

with a compound of formula (7):

or pharmaceutically acceptable salt thereof, in the presence of Lewisacid, to obtain a compound of formula (5), or pharmaceuticallyacceptable salt thereof.
 2. The method of claim 1, wherealpha-glycosylation is achieved using TMSOTf, Tf₂O, BF₃.OEt₂, orMe₂S₂-Tf₂O as the Lewis acid; and optionally, using molecular sieves tode-hydrate.
 3. The method of claim 1, wherein the compound of formula(6) is (A5):

or a pharmaceutically acceptable salt thereof; the compound of formula(7) is (A4):

or a pharmaceutically acceptable salt thereof; and the compound offormula (5) is (A6):

or a pharmaceutically acceptable salt thereof.
 4. The method of claim 1further comprising a step of reducing a compound of formula (5):

or pharmaceutically acceptable salt thereof, to provide the compound offormula (3):

or pharmaceutically acceptable salt thereof.
 5. The method of claim 4,wherein the step of reducing is achieved using lithium aluminum hydride,sodium borohydride, a borane complex, a phosphine complex, an enzymereduction, hydrogenation, or transfer hydrogenation.
 6. The method ofclaim 4, wherein the compound of formula (5) is (A6):

or a pharmaceutically acceptable salt thereof; and the compound offormula (3) is (A7):

or a pharmaceutically acceptable salt thereof.
 7. The method of claim 4further comprising a step of coupling a compound of formula (3):

or pharmaceutically acceptable salt thereof, with a compound of formula(4):

or pharmaceutically acceptable salt thereof, in the presence of acoupling reagent, to yield a compound of formula (2):

or pharmaceutically acceptable salt thereof; wherein: X is an alkyl oralkenyl group; R₃ is H or OH; R₄ is H or OH; and R₅ is aryl, substitutedaryl, heteroaryl, or substituted heteroaryl.
 8. The method of claim 7,wherein the coupling reagent is HBTU.
 9. The method of claim 7, whereinthe compound of formula (3) is (A7):

or a pharmaceutically acceptable salt thereof; the compound of formula(4) is (B4):

or a pharmaceutically acceptable salt thereof; and the compound offormula (2) is (A8):

or a pharmaceutically acceptable salt thereof.
 10. The method of claim 7further comprising a step of deprotecting a compound of formula (2):

or pharmaceutically acceptable salt thereof, wherein PG is a hydroxylprotecting group and X is an alkyl or alkenyl group, with hydrogen underhydrogenation catalysis, to provide a compound of formula (1):

or pharmaceutically acceptable salt thereof; wherein: R₁ is OH; X is analkyl group; R₃ is OH or H; R₄ is OH or H; and R₅ is aryl, substitutedaryl, heteroaryl, or substituted heteroaryl.
 11. The method of claim 10,wherein the hydrogenation catalyst is selected from Pd/C, Pd(OH₂), orRaney-Ni.
 12. The method of claim 10, wherein the compound of formula(2) is (A8):

or a pharmaceutically acceptable salt thereof; and the compound offormula (1) is (C34):

or a pharmaceutically acceptable salt thereof.